<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Antimicrob Chemother</journal-id><journal-id journal-id-type="iso-abbrev">J. Antimicrob. Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">748</journal-id><journal-id journal-id-type="pmc-domain">jac</journal-id><journal-id journal-id-type="publisher-id">jac</journal-id><journal-title-group><journal-title>Journal of Antimicrobial Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0305-7453</issn><issn pub-type="epub">1460-2091</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6814093</article-id><article-id pub-id-type="pmcid-ver">PMC6814093.1</article-id><article-id pub-id-type="pmcaid">6814093</article-id><article-id pub-id-type="pmcaiid">6814093</article-id><article-id pub-id-type="pmid">31127283</article-id><article-id pub-id-type="doi">10.1093/jac/dkz221</article-id><article-id pub-id-type="publisher-id">dkz221</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5066-1654</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yuanyuan</given-names></name><xref ref-type="aff" rid="dkz221-aff1">1</xref><xref ref-type="corresp" rid="dkz221-cor1"/><xref ref-type="author-notes" rid="dkz221-FM1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bahar</surname><given-names initials="MA">Muh Akbar</given-names></name><xref ref-type="aff" rid="dkz221-aff1">1</xref><xref ref-type="aff" rid="dkz221-aff2">2</xref><xref ref-type="author-notes" rid="dkz221-FM1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jansen</surname><given-names initials="AME">Anouk M E</given-names></name><xref ref-type="aff" rid="dkz221-aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kocks</surname><given-names initials="JWH">Janwillem W H</given-names></name><xref ref-type="aff" rid="dkz221-aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6703-0288</contrib-id><name name-style="western"><surname>Alffenaar</surname><given-names initials="JWC">Jan-Willem C</given-names></name><xref ref-type="aff" rid="dkz221-aff4">4</xref><xref ref-type="aff" rid="dkz221-aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hak</surname><given-names initials="E">Eelko</given-names></name><xref ref-type="aff" rid="dkz221-aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wilffert</surname><given-names initials="B">Bob</given-names></name><xref ref-type="aff" rid="dkz221-aff1">1</xref><xref ref-type="aff" rid="dkz221-aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Borgsteede</surname><given-names initials="SD">Sander D</given-names></name><xref ref-type="aff" rid="dkz221-aff6">6</xref><xref ref-type="aff" rid="dkz221-aff7">7</xref></contrib></contrib-group><aff id="dkz221-aff1"><label>1</label>Department of PharmacoTherapy, -Epidemiology &amp; -Economics, <institution>Groningen Research Institute of Pharmacy</institution>, University of Groningen, Groningen, The Netherlands</aff><aff id="dkz221-aff2"><label>2</label>Faculty of Pharmacy, <institution>Hasanuddin University</institution>, Makassar, Indonesia</aff><aff id="dkz221-aff3"><label>3</label>Department of General Practice and Elderly Care Medicine, <institution>Groningen Research Institute for Asthma and COPD</institution>, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands</aff><aff id="dkz221-aff4"><label>4</label>Department of Clinical Pharmacy &amp; Pharmacology, <institution>University Medical Center Groningen</institution>, University of Groningen, Groningen, The Netherlands</aff><aff id="dkz221-aff5"><label>5</label>Faculty of Medicine and Health, <institution>School of Pharmacy and Westmead Hospital</institution>, University of Sydney, Sydney, Australia</aff><aff id="dkz221-aff6"><label>6</label>Department of Clinical Decision Support, <institution>Health Base Foundation</institution>, Houten, The Netherlands</aff><aff id="dkz221-aff7"><label>7</label>Department of Hospital Pharmacy, <institution>Erasmus University Medical Center, Rotterdam</institution>, The Netherlands</aff><author-notes><corresp id="dkz221-cor1">Corresponding author. Unit of PharmacoTherapy, -Epidemiology &amp; -Economics (PTEE), Groningen Research Institute of Pharmacy, University of Groningen, P.O. Box 196, 9700 AD Groningen, The Netherlands. Tel: +31(0)50-363-9163; Fax: +31(0)50-363-2772; E-mail: <email>yuanyuan.wang@rug.nl</email> or <email>yuanyuanwang.research@gmail.com</email>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-5066-1654">orcid.org/0000-0002-5066-1654</ext-link></corresp><fn id="dkz221-FM1"><p>Yuanyuan Wang and Muh. Akbar Bahar authors made an equal contribution.</p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2019</year></pub-date><pub-date pub-type="epub" iso-8601-date="2019-05-24"><day>24</day><month>5</month><year>2019</year></pub-date><volume>74</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">342473</issue-id><fpage>2848</fpage><lpage>2864</lpage><history><date date-type="received"><day>17</day><month>9</month><year>2018</year></date><date date-type="rev-request"><day>21</day><month>11</month><year>2018</year></date><date date-type="rev-recd"><day>13</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>26</day><month>4</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>05</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>30</day><month>10</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-03 23:25:10.063"><day>03</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.</copyright-statement><copyright-year>2019</copyright-year><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the
original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="dkz221.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dkz221.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Guidelines advise the use of antibacterials (ABs) in the management of COPD exacerbations. COPD patients often have multiple comorbidities, such as diabetes mellitus and cardiac diseases, leading to polypharmacy. Consequently, drug&#8211;drug interactions (DDIs) may frequently occur, and may cause serious adverse events and treatment failure.</p></sec><sec id="s2"><title>Objectives</title><p>(i) To review DDIs related to frequently prescribed ABs among COPD patients from observational and clinical studies. (ii) To improve AB prescribing safety in clinical practice by structuring DDIs according to comorbidities of COPD.</p></sec><sec id="s3"><title>Methods</title><p>We conducted a systematic review by searching PubMed and Embase up to 8 February 2018 for clinical trials, cohort and case&#8211;control studies reporting DDIs of ABs used for COPD. Study design, subjects, sample size, pharmacological mechanism of DDI and effect of interaction were extracted. We evaluated levels of DDIs and quality of evidence according to established criteria and structured the data by possible comorbidities.</p></sec><sec id="s4"><title>Results</title><p>In all, 318 articles were eligible for review, describing a wide range of drugs used for comorbidities and their potential DDIs with ABs. DDIs between ABs and co-administered drugs could be subdivided into: (i) co-administered drugs altering the pharmacokinetics of ABs; and (ii) ABs interfering with the pharmacokinetics of co-administered drugs. The DDIs could lead to therapeutic failures or toxicities.</p></sec><sec id="s5"><title>Conclusions</title><p>DDIs related to ABs with clinical significance may involve a wide range of indicated drugs to treat comorbidities in COPD. The evidence presented can support (computer-supported) decision-making by health practitioners when prescribing ABs during COPD exacerbations in the case of co-medication.</p></sec></abstract><funding-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">China Scholarship Council</named-content><named-content content-type="funder-identifier">10.13039/501100004543</named-content></funding-source><award-id>201506010259</award-id></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">University of Groningen</named-content></funding-source></award-group></funding-group><counts><page-count count="17"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>COPD is a complex respiratory disorder characterized by persistent respiratory symptoms and airflow limitation.<xref rid="dkz221-B1" ref-type="bibr"><sup>1</sup></xref> The chronic and progressive course of COPD is frequently aggravated by exacerbation, defined as an acute worsening of respiratory symptoms, such as increased cough, dyspnoea and production of sputum.<xref rid="dkz221-B2" ref-type="bibr"><sup>2</sup></xref> Exacerbations of COPD can be triggered by respiratory tract infections; 40%&#8211;60% of exacerbations are caused by bacteria, especially <italic toggle="yes">Haemophilus influenzae, Streptococcus pneumoniae</italic> and <italic toggle="yes">Moraxella catarrhalis.</italic><xref rid="dkz221-B3" ref-type="bibr"><sup>3</sup></xref> Evidence from randomized controlled trials indicated that use of antibacterials (ABs) may reduce the frequency and severity of COPD exacerbations.<xref rid="dkz221-B4" ref-type="bibr"><sup>4&#8211;6</sup></xref> Therefore, guidelines have recommended involving ABs in the therapeutic and preventive management of COPD exacerbations.<xref rid="dkz221-B1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="dkz221-B7" ref-type="bibr"><sup>7</sup></xref></p><p>Patients with COPD often suffer from multiple morbidities.<xref rid="dkz221-B8" ref-type="bibr"><sup>8</sup></xref> Hence, polypharmacy is common and contributes to drug&#8211;drug interactions (DDIs). Adverse drug reactions (ADRs) or therapeutic failure may be the result of interactions between ABs and co-administered drugs. In addition, COPD is an age-related disease and the elderly are more susceptible to the effect of DDIs because of gradual physiological changes affecting pharmacokinetics and pharmacodynamics.<xref rid="dkz221-B9" ref-type="bibr"><sup>9</sup></xref></p><p>The objectives of this study were to: (i) systematically review DDIs related to frequently prescribed ABs among COPD patients from observational and clinical studies; and (ii) improve AB prescribing safety in clinical practice by structuring DDIs according to comorbidities of COPD. Studies without comparison groups, and therefore with low quality of the causal evidence, such as case reports about QT-interval prolonging interactions, are not included in this review. A DDI handbook such as <italic toggle="yes">Stockley&#8217;s Drug Interactions</italic> and the official product information should be referred to for the clinical impact of these kinds of interaction.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Search strategy</title><p>We conducted a systematic review following the PRISMA guideline. PubMed and Embase databases were searched for related articles published in English up to 8 February 2018 using key terms &#8216;drug interactions&#8217;, &#8216;pharmacokinetics&#8217; and &#8216;pharmacodynamics&#8217;, and a list of most frequently used ABs for COPD (Table&#160;<xref rid="dkz221-T1" ref-type="table">1</xref>). The ABs were selected based on two related Cochrane reviews and their prescription frequency in the University of Groningen prescription database IADB.nl (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.iadb.nl/">http://www.iadb.nl/</ext-link>) covering drug prescriptions for &#8764;700000 people.<xref rid="dkz221-B4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="dkz221-B5" ref-type="bibr"><sup>5</sup></xref> Additionally, we checked the primary sources of signals from Dutch DDI alert systems: G-Standard and Pharmabase.<xref rid="dkz221-B10" ref-type="bibr"><sup>10</sup></xref> Reference lists from eligible studies were also tracked for additional qualified papers. Full search details are provided in the <xref ref-type="supplementary-material" rid="sup1">Supplementary data</xref>, available at <italic toggle="yes">JAC</italic> Online.
</p><table-wrap id="dkz221-T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>ABs included in the study that are frequently prescribed among COPD patients<xref ref-type="table-fn" rid="tblfn1"><sup>a</sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Category</th><th rowspan="1" colspan="1">Sub-category</th><th rowspan="1" colspan="1">ABs included</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">&#946;-Lactam</td><td rowspan="1" colspan="1">penicillin</td><td rowspan="1" colspan="1">amoxicillin/clavulanic acid (co-amoxiclav), amoxicillin, flucloxacillin, pheneticillin, phenoxymethylpenicillin (penicillin V)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">cephalosporin</td><td rowspan="1" colspan="1">cefaclor, cefuroxime, ceftriaxone, cefradine, ceftazidime</td></tr><tr><td rowspan="1" colspan="1">Macrolide</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">erythromycin, clarithromycin, azithromycin, roxithromycin, clindamycin</td></tr><tr><td rowspan="1" colspan="1">Tetracycline</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">tetracycline, doxycycline, minocycline</td></tr><tr><td rowspan="1" colspan="1">Quinolone</td><td rowspan="1" colspan="1">fluoroquinolone</td><td rowspan="1" colspan="1">ciprofloxacin, moxifloxacin, levofloxacin, ofloxacin, norfloxacin</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">other quinolone</td><td rowspan="1" colspan="1">pipemidic acid</td></tr><tr><td rowspan="1" colspan="1">Sulphonamide</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">sulfamethoxazole</td></tr><tr><td rowspan="1" colspan="1">Others</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">nitrofurantoin, methenamine, trimethoprim</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p>Based on two Cochrane reviews<xref rid="dkz221-B4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="dkz221-B5" ref-type="bibr"><sup>5</sup></xref> and use within the University of Groningen (the Netherlands) prescription database, IADB.nl (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.iadb.nl/">http://www.iadb.nl/</ext-link>).</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Study selection criteria</title><p>Eligible studies met the following criteria: (i) DDIs in humans; (ii) involving the targeted ABs; and (iii) being clinical trials, randomized controlled trials or cohort or case&#8211;control studies. We excluded case reports and other descriptive studies. We further excluded studies with subjects whose pharmacokinetics and pharmacodynamics were not comparable to those of general COPD patients, e.g. newborn babies, pregnant women and patients with severe renal/hepatic impairment. Other exclusion criteria were: (i) unregistered drugs (by FDA or EMA); (ii) involving three or more drug interactions; and (iii) not DDIs (food&#8211;drug or gene&#8211;drug interactions); (iv) not original studies (reviews, letters and editorials). Pharmacodynamic interactions were beyond the scope of this review and were excluded.</p></sec><sec><title>Data extraction and quality assessment</title><p>All records were exported to Refworks; titles and abstracts were screened by Y. W. and A. M. E. J. independently. Full-text papers were obtained for records that were considered of potential relevance by at least one of the reviewers. Final decisions were made by consensus between two reviewers according to the preset criteria. Discrepancies between reviewers were resolved by discussion; a third reviewer (E. H.) was asked if no consensus was reached. Information about names of ABs and related interacting drugs, study design, study subjects, sample size, interacting mechanism, effects of interaction and recommendation by study authors were extracted by the same reviewers (Y. W. and A. M. E. J.) and checked by another reviewer (M. A. B.). Quality of evidence was evaluated by grading 0&#8211;4 based on criteria (Table&#160;<xref rid="dkz221-T2" ref-type="table">2</xref>) used by previous studies.<xref rid="dkz221-B11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="dkz221-B12" ref-type="bibr"><sup>12</sup></xref></p><table-wrap id="dkz221-T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Quality of evidence for DDIs<xref rid="dkz221-B11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="dkz221-B12" ref-type="bibr"><sup>12</sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Definition</th><th rowspan="1" colspan="1">Score</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Clinical research with appropriate control group and relevant pharmacokinetics and/or pharmacodynamic parameters. The studies meet all of the criteria below:
<list list-type="bullet"><list-item><p>The interacting effect of concomitant medication with investigated drugs is reported in the manuscript.</p></list-item><list-item><p>All potential confounders are mentioned and taken into account (for example smoking behaviour or renal function).</p></list-item><list-item><p>The results of interaction are based on the steady-state kinetics.</p></list-item><list-item><p>Variation in dose was adjusted.</p></list-item></list></td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Clinical research with appropriate control group and relevant pharmacokinetics and/or pharmacodynamic parameters that does not meet one or more of the pre-defined criteria above.</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Complete observational studies with clinically relevant results.</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Incomplete observational studies. (e.g. without controlling confounders or presence of other explanatory factors for the adverse reaction), case reports, summary of product characteristics.</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">In vitro</italic> studies, <italic toggle="yes">in vivo</italic> animal studies, prediction modelling studies.</td><td rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap><p>The strengths of the DDIs were classified into four levels (1, strong; 2, substantial; 3, moderate; 4, weak/no) according to preset published criteria (Table&#160;<xref rid="dkz221-T3" ref-type="table">3</xref>).<xref rid="dkz221-B12" ref-type="bibr"><sup>12</sup></xref> In the cases of several studies on the same DDI combination, we categorized the DDI based on the highest level of severity. Considering that drugs with a narrow therapeutic index (NTI) are more vulnerable to DDIs, the strength of the DDI for such drugs was upgraded one level.<xref rid="dkz221-B12" ref-type="bibr"><sup>12</sup></xref></p><table-wrap id="dkz221-T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Description of level of DDIs<xref rid="dkz221-B10" ref-type="bibr"><sup>10</sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Definition</th><th rowspan="1" colspan="1">AUC</th><th rowspan="1" colspan="1">Clearance</th><th rowspan="1" colspan="1">Score<xref ref-type="table-fn" rid="tblfn3"><sup>a</sup></xref></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Involved inhibitor</td><td rowspan="1" colspan="1">&gt;200% &#8593;</td><td rowspan="1" colspan="1">&#8595; &gt;67%</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Involved inducer</td><td rowspan="1" colspan="1">&gt;90% &#8595;</td><td rowspan="1" colspan="1">&#8593; &#8805;900%</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">For observational studies, RR/OR &#8805;10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Involved inhibitor</td><td rowspan="1" colspan="1">75%&#8211;200% &#8593;</td><td rowspan="1" colspan="1">&#8595; &#8805;43% to &lt;67%</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Involved inducer</td><td rowspan="1" colspan="1">60%&#8211;90% &#8595;</td><td rowspan="1" colspan="1">&#8593; &#8805;150% to &lt;900%</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">For observational studies, RR/OR 3&#8211;9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Involved inhibitor</td><td rowspan="1" colspan="1">25%&#8211;75% &#8593;</td><td rowspan="1" colspan="1">&#8595; &#8805;20% to &lt;43%</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Involved inducer</td><td rowspan="1" colspan="1">25%&#8211;60% &#8595;</td><td rowspan="1" colspan="1">&#8593; &#8805;33% to &lt;150%</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">For observational studies, RR/OR 1.5&#8211;2.9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Involved inducer/inhibitor</td><td rowspan="1" colspan="1">&lt;25% change</td><td rowspan="1" colspan="1">&#8595; &lt;20% or &#8593; &lt;33%</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">For observational studies, RR/OR &lt;1.5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">&#8195;(a) For interacting drugs with an NTI, the degree of DDIs will be improved to the level one higher</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">exception</td></tr><tr><td rowspan="1" colspan="1">&#8195;(b) If the DDI level cannot be judged by the above criteria, we assessed it by discussion based on available data and evidence</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">exception</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>RR, relative risk; OR, odds ratio; &#8593;, increase; &#8595;, decrease.</p></fn><fn id="tblfn3"><label>a</label><p>1, strong interaction; 2, substantial interaction; 3, moderate interaction; and 4, weak/no interaction.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Publications identified by literature search</title><p>Our search yielded 1412 and 1734 studies from PubMed and Embase, respectively (Figure&#160;<xref ref-type="fig" rid="dkz221-F1">1</xref>). After removing duplicates, 2560 articles were screened by title and abstract, of which 630 papers were included for full-text screening, resulting in 282 eligible articles. With 36 studies identified from other resources, we finally obtained 318 studies for assessment in this review.
</p><fig id="dkz221-F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Flow chart of study selection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dkz221f1.jpg"/></fig><p>The interacting drugs, underlying mechanisms, levels and practice recommendations for the DDIs are presented in Table&#160;<xref rid="dkz221-T4" ref-type="table">4</xref>. Details on individual studies of DDIs with a potential clinical significance (levels 1&#8211;3) are presented in Tables <xref ref-type="supplementary-material" rid="sup1">S1 and S2</xref> and the data on studies with a low level of DDIs (weak or no interaction) are presented in Table <xref ref-type="supplementary-material" rid="sup1">S3</xref>.
</p><table-wrap id="dkz221-T4" orientation="portrait" position="float"><label>Table 4.</label><caption><p>DDIs of antibacterials (ABs) for COPD exacerbation and other drugs for treating its comorbidities</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Comorbidity</th><th rowspan="1" colspan="1">Medication</th><th rowspan="1" colspan="1">Interacting AB</th><th rowspan="1" colspan="1">Mechanism</th><th rowspan="1" colspan="1">Management suggestions</th><th rowspan="1" colspan="1">Level of interaction<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></th><th rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="8" colspan="1">
<italic toggle="yes">Diabetes Antidiabetic medication</italic>
</td><td rowspan="1" colspan="1">glipizide, glyburide</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of CYP2C9.</td><td rowspan="2" colspan="1">Consider alternative or adjusted dose of substrate or use cautiously by monitoring patient's blood glucose.</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">
<xref rid="dkz221-B16" ref-type="bibr">
<sup>16&#8211;19</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">glyburide</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of P-gp.</td></tr><tr><td rowspan="1" colspan="1">glipizide, glyburide</td><td rowspan="1" colspan="1">levofloxacin</td><td rowspan="1" colspan="1">Inhibition of P-gp.</td><td rowspan="6" colspan="1">Monitor patient's blood glucose and if necessary adjust dose of substrate.</td><td rowspan="6" colspan="1">3</td><td rowspan="6" colspan="1">
<xref rid="dkz221-B16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B20" ref-type="bibr">
<sup>20&#8211;26</sup>
</xref>
</td></tr><tr><td rowspan="2" colspan="1">tolbutamide</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 and P-gp.</td></tr><tr><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of CYP2C9.</td></tr><tr><td rowspan="1" colspan="1">glipizide, repaglinide</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td></tr><tr><td rowspan="1" colspan="1">repaglinide, rosiglitazone</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of CYP2C8.</td></tr><tr><td rowspan="1" colspan="1">metformin</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of OCT2 and MATE1.</td></tr><tr><td colspan="7" rowspan="1">Heart and circulatory system diseases</td></tr><tr><td rowspan="3" colspan="1">
<italic toggle="yes">Antihypertensive agents</italic>
</td><td rowspan="1" colspan="1">spironolactone</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of potassium secretion.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor potassium plasma levels.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B32" ref-type="bibr">
<sup>32</sup>
</xref>
</td></tr><tr><td rowspan="2" colspan="1">calcium channel blocker</td><td rowspan="1" colspan="1">erythromycin, clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B27" ref-type="bibr">
<sup>27&#8211;29</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">azithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Monitor side effects and if necessary adjust dose of substrate.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B27" ref-type="bibr">
<sup>27</sup>
</xref>
</td></tr><tr><td rowspan="4" colspan="1">
<italic toggle="yes">Lipid-lowering drugs</italic>
</td><td rowspan="1" colspan="1">simvastatin</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor side effects.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B34" ref-type="bibr">
<sup>34</sup>
</xref>
</td></tr><tr><td rowspan="2" colspan="1">atorvastatin</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B35" ref-type="bibr">
<sup>35</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="2" colspan="1">Monitor side effects and if necessary adjust dose of substrate.</td><td rowspan="2" colspan="1">3</td><td rowspan="2" colspan="1">
<xref rid="dkz221-B36" ref-type="bibr">
<sup>36</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B204" ref-type="bibr">
<sup>204</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">rosuvastatin/pravastatin/fluvastatin</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of OAT.</td></tr><tr><td rowspan="5" colspan="1">
<italic toggle="yes">Oral anticoagulants</italic>
</td><td rowspan="3" colspan="1">warfarin, phenprocoumon /acenocoumarol</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of CYP2C9.</td><td rowspan="1" colspan="1">Avoid combination or closely monitor the change of INR routinely and adjust dose if needed.</td><td rowspan="1" colspan="1">1</td><td rowspan="3" colspan="1">
<xref rid="dkz221-B39" ref-type="bibr">
<sup>39&#8211;58</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">amoxicillin/co- amoxiclav, ceftriaxone</td><td rowspan="1" colspan="1">Alterations in normal gut flora.</td><td rowspan="2" colspan="1">Choose alternative AB or, if not possible, monitor the change of INR routinely.</td><td rowspan="2" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">clarithromycin, azithromycin, ciprofloxacin, levofloxacin, ofloxacin, doxycycline</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 or alterations in normal gut flora.</td></tr><tr><td rowspan="1" colspan="1">edoxaban, dabigatran, rivaroxaban</td><td rowspan="1" colspan="1">erythromycin, clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 and/or P-gp.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate or monitor signs of excessive anticoagulant effect.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B62" ref-type="bibr">
<sup>62</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B63" ref-type="bibr">
<sup>63</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">warfarin</td><td rowspan="1" colspan="1">moxifloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 or alterations in normal gut flora.</td><td rowspan="1" colspan="1">Monitor the change of INR routinely.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B41" ref-type="bibr">
<sup>41</sup>
</xref>
</td></tr><tr><td rowspan="5" colspan="1">
<italic toggle="yes">Antiarrhythmic agents</italic>
</td><td rowspan="1" colspan="1">digoxin</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of P-gp.</td><td rowspan="1" colspan="1">Avoid combination or perform TDM and if necessary adjust dose of substrate.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B68" ref-type="bibr">
<sup>68&#8211;71</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">quinidine, lignocaine</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="2" colspan="1">Consider alternative or perform TDM and if necessary adjust dose of substrate.</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">
<xref rid="dkz221-B64" ref-type="bibr">
<sup>64&#8211;67</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">procainamide</td><td rowspan="1" colspan="1">TMP</td><td rowspan="1" colspan="1">Inhibition of tubular secretion.</td></tr><tr><td rowspan="1" colspan="1">pindolol, digoxin</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of tubular secretion.</td><td rowspan="2" colspan="1">Perform TDM and if necessary adjust dose of substrate.</td><td rowspan="2" colspan="1">3</td><td rowspan="2" colspan="1">
<xref rid="dkz221-B72" ref-type="bibr">
<sup>72&#8211;75</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">procainamide</td><td rowspan="1" colspan="1">levofloxacin, ofloxacin</td><td rowspan="1" colspan="1">Inhibition of OCT.</td></tr><tr><td colspan="7" rowspan="1">Respiratory diseases</td></tr><tr><td rowspan="5" colspan="1">
<italic toggle="yes">Medication for obstructive airways diseases</italic>
</td><td rowspan="1" colspan="1">methylprednisolone, montelukast</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 and P-gp.</td><td rowspan="3" colspan="1">Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects. For theophylline, perform TDM.</td><td rowspan="3" colspan="1">2</td><td rowspan="3" colspan="1">
<xref rid="dkz221-B78" ref-type="bibr">
<sup>78&#8211;85</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B90" ref-type="bibr">
<sup>90&#8211;97</sup>
</xref>
</td></tr><tr><td rowspan="2" colspan="1">theophylline</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td></tr><tr><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP1A2.</td></tr><tr><td rowspan="1" colspan="1">loratadine</td><td rowspan="1" colspan="1">erythromycin, clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="2" colspan="1">Monitor side effects and if necessary adjust dose of substrate.</td><td rowspan="2" colspan="1">3</td><td rowspan="2" colspan="1">
<xref rid="dkz221-B86" ref-type="bibr">
<sup>86</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B87" ref-type="bibr">
<sup>87</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">roflumilast</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td></tr><tr><td rowspan="5" colspan="1">
<italic toggle="yes">Anti-TB drugs</italic>
</td><td rowspan="1" colspan="1">rifabutin</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Avoid combination.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B101" ref-type="bibr">
<sup>101</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B110" ref-type="bibr">
<sup>110</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B111" ref-type="bibr">
<sup>111</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">rifampicin, rifabutin</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Induction of CYP3A4.</td><td rowspan="1" colspan="1">Consider alternative AB for COPD</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B100" ref-type="bibr">
<sup>100</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B101" ref-type="bibr">
<sup>101</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">rifampicin, rifabutin</td><td rowspan="1" colspan="1">TMP/SMX, doxycycline</td><td rowspan="1" colspan="1">Induction of CYP3A4/CYP2C9.</td><td rowspan="3" colspan="1">Consider alternative AB for COPD or monitor the effectiveness of AB and if necessary adjust dose of AB.</td><td rowspan="3" colspan="1">3</td><td rowspan="3" colspan="1">
<xref rid="dkz221-B102" ref-type="bibr">
<sup>102&#8211;104</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B106" ref-type="bibr">
<sup>106&#8211;109</sup>
</xref>
</td></tr><tr><td rowspan="2" colspan="1">rifampicin</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of mixed oxidases.</td></tr><tr><td rowspan="1" colspan="1">moxifloxacin</td><td rowspan="1" colspan="1">Induction of phase II enzymes.</td></tr><tr><td colspan="7" rowspan="1">Neurological disorders</td></tr><tr><td rowspan="2" colspan="1">
<italic toggle="yes">Anti-Parkinson&#8217;s agents</italic>
</td><td rowspan="1" colspan="1">bromocriptine</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor side effects.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B112" ref-type="bibr">
<sup>112</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">cabergoline</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 and P-gp.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B113" ref-type="bibr">
<sup>113</sup>
</xref>
</td></tr><tr><td rowspan="4" colspan="1">
<italic toggle="yes">Antiepileptic drugs</italic>
</td><td rowspan="1" colspan="1">carbamazepine, phenytoin</td><td rowspan="1" colspan="1">doxycycline</td><td rowspan="1" colspan="1">Induction of CYP3A4.</td><td rowspan="1" colspan="1">Consider alternative or perform TDM.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B116" ref-type="bibr">
<sup>116</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B117" ref-type="bibr">
<sup>117</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">carbamazepine</td><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4/1A2.</td><td rowspan="1" colspan="1">Consider alternative or perform TDM.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B118" ref-type="bibr">
<sup>118</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">phenytoin</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of CYP2C8.</td><td rowspan="1" colspan="1">Consider alternative or perform TDM.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B116" ref-type="bibr">
<sup>116</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B119" ref-type="bibr">
<sup>119</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">phenobarbital</td><td rowspan="1" colspan="1">doxycycline</td><td rowspan="1" colspan="1">Induction of CYP3A4.</td><td rowspan="1" colspan="1">Monitor side effects and if necessary adjust dose of substrate.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B115" ref-type="bibr">
<sup>115</sup>
</xref>
</td></tr><tr><td colspan="7" rowspan="1">Depression and psychiatric disorders</td></tr><tr><td rowspan="5" colspan="1">
<italic toggle="yes">Antidepressant, anxiolytic and antipsychotic agents</italic>
</td><td rowspan="1" colspan="1">buspirone</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor side effects.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B125" ref-type="bibr">
<sup>125</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">quetiapine</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="3" colspan="1">Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects. For clozapine, perform TDM.</td><td rowspan="3" colspan="1">2</td><td rowspan="3" colspan="1">
<xref rid="dkz221-B122" ref-type="bibr">
<sup>122&#8211;124</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B129" ref-type="bibr">
<sup>129</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">pimozide, trazodone</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td></tr><tr><td rowspan="1" colspan="1">clozapine</td><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP1A2.</td></tr><tr><td rowspan="1" colspan="1">diazepam</td><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Monitor side effects and if necessary adjust the dose of substrate.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B127" ref-type="bibr">
<sup>127</sup>
</xref>
</td></tr><tr><td colspan="7" rowspan="1">Dyspepsia</td></tr><tr><td rowspan="4" colspan="1">
<italic toggle="yes">Antidyspepsia medications</italic>
</td><td rowspan="1" colspan="1">aluminium hydroxide, sucralfate</td><td rowspan="1" colspan="1">quinolone, tetracyclines</td><td rowspan="1" colspan="1">Complex formation.</td><td rowspan="1" colspan="1">Avoid combination or administer quinolone at least 2&#8201;h before or 6&#8201;h after co-agents.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B131" ref-type="bibr">
<sup>131&#8211;142</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">lansoprazole</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B147" ref-type="bibr">
<sup>147</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">calcium carbonate</td><td rowspan="1" colspan="1">quinolone, tetracyclines</td><td rowspan="1" colspan="1">Complex formation.</td><td rowspan="1" colspan="1">Avoid co-administration or administer at interval of at least 2&#8201;h.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B131" ref-type="bibr">
<sup>131</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B139" ref-type="bibr">
<sup>139</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">bismuth subsalicylate</td><td rowspan="1" colspan="1">quinolone, tetracyclines</td><td rowspan="1" colspan="1">Complex formation.</td><td rowspan="1" colspan="1">Administration interval of at least 2&#8201;h.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B143" ref-type="bibr">
<sup>143</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B205" ref-type="bibr">
<sup>205</sup>
</xref>
</td></tr><tr><td colspan="7" rowspan="1">HIV</td></tr><tr><td rowspan="3" colspan="1">
<italic toggle="yes">Anti-HIV drugs</italic>
</td><td rowspan="1" colspan="1">didanosine</td><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Complex formation.</td><td rowspan="1" colspan="1">Avoid combination or administer quinolone at least 2&#8201;h before or 6&#8201;h after co-agents.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B149" ref-type="bibr">
<sup>149</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B150" ref-type="bibr">
<sup>150</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">saquinavir</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B151" ref-type="bibr">
<sup>151</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">lamivudine, didanosine</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of tubular secretion.</td><td rowspan="1" colspan="1">Monitor side effects and if necessary adjust dose of substrate.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B152" ref-type="bibr">
<sup>152</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B153" ref-type="bibr">
<sup>153</sup>
</xref>
</td></tr><tr><td colspan="7" rowspan="1">Other</td></tr><tr><td rowspan="2" colspan="1">
<italic toggle="yes">Pulmonary arterial hypertension medications</italic>
</td><td rowspan="1" colspan="1">bosentan</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 and P-gp.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor side effects.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B206" ref-type="bibr">
<sup>206</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">ambrisentan</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 and P-gp.</td><td rowspan="1" colspan="1">Monitor side effects and if necessary adjust dose of substrate.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B207" ref-type="bibr">
<sup>207</sup>
</xref>
</td></tr><tr><td rowspan="2" colspan="1">
<italic toggle="yes">Insomnia medications</italic>
</td><td rowspan="1" colspan="1">brotizolam, triazolam, zopiclone</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Consider an alternative AB or other hypnotic drugs (not a CYP3A4 substrate).</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B208" ref-type="bibr">
<sup>208&#8211;210</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">zolpidem</td><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Monitor side effects and if necessary choose alternative AB or other hypnotic drugs (not a CYP3A4 substrate).</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B211" ref-type="bibr">
<sup>211</sup>
</xref>
</td></tr><tr><td rowspan="2" colspan="1">
<italic toggle="yes">Antifungal agents</italic>
</td><td rowspan="1" colspan="1">voriconazole</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="2" colspan="1">Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects. For voriconazole, perform TDM and adjust dose if needed.</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">
<xref rid="dkz221-B154" ref-type="bibr">
<sup>154</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B155" ref-type="bibr">
<sup>155</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">itraconazole</td><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Antineoplastic drugs</italic>
</td><td rowspan="1" colspan="1">vinorelbine</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 and P-gp.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor side effects.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B179" ref-type="bibr">
<sup>179</sup>
</xref>
</td></tr><tr><td rowspan="3" colspan="1">
<italic toggle="yes">Anti-gout drugs</italic>
</td><td rowspan="2" colspan="1">colchicine</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Avoid combination or perform TDM and adjust dose if needed.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B180" ref-type="bibr">
<sup>180</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">azithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B180" ref-type="bibr">
<sup>180</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">probenecid</td><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of OAT.</td><td rowspan="1" colspan="1">Monitor side effects and if necessary adjust dose of substrate.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B194" ref-type="bibr">
<sup>194</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B195" ref-type="bibr">
<sup>195</sup>
</xref>
</td></tr><tr><td rowspan="6" colspan="1">
<italic toggle="yes">Anaesthesia drugs</italic>
</td><td rowspan="1" colspan="1">midazolam</td><td rowspan="1" colspan="1">clarithromycin, erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor side effects.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B156" ref-type="bibr">
<sup>156&#8211;160</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">ketamine</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Consider alternative or perform TDM and adjust dose if needed.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B161" ref-type="bibr">
<sup>161</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">alfentanil</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="4" colspan="1">Monitor side effects and if necessary adjust dose of substrate.</td><td rowspan="4" colspan="1">3</td><td rowspan="4" colspan="1">
<xref rid="dkz221-B162" ref-type="bibr">
<sup>162&#8211;166</sup>
</xref>
</td></tr><tr><td rowspan="2" colspan="1">ropivacaine</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td></tr><tr><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP1A2.</td></tr><tr><td rowspan="1" colspan="1">midazolam</td><td rowspan="1" colspan="1">roxithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Analgesics</italic>
</td><td rowspan="1" colspan="1">oxycodone</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor side effects.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B167" ref-type="bibr">
<sup>167</sup>
</xref>
</td></tr><tr><td rowspan="4" colspan="1">
<italic toggle="yes">Immunosuppressant drugs</italic>
</td><td rowspan="1" colspan="1">cyclosporine</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="2" colspan="1">Avoid combination or adjust dose of substrates and perform TDM.</td><td rowspan="2" colspan="1">1</td><td rowspan="2" colspan="1">
<xref rid="dkz221-B168" ref-type="bibr">
<sup>168</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B169" ref-type="bibr">
<sup>169</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B181" ref-type="bibr">
<sup>181</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B182" ref-type="bibr">
<sup>182</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">everolimus</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 and/ P-gp.</td></tr><tr><td rowspan="1" colspan="1">tacrolimus</td><td rowspan="1" colspan="1">levofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 or P-gp.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B170" ref-type="bibr">
<sup>170</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">cyclosporine</td><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Monitor side effects and, if necessary adjust dose of substrate.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B171" ref-type="bibr">
<sup>171</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B172" ref-type="bibr">
<sup>172</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Vasoactive agents</italic>
</td><td rowspan="1" colspan="1">sildenafil</td><td rowspan="1" colspan="1">clarithromycin, erythromycin, ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B173" ref-type="bibr">
<sup>173</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B174" ref-type="bibr">
<sup>174</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Appetite suppressants</italic>
</td><td rowspan="1" colspan="1">sibutramine</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4 and P-gp.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor side effects.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B175" ref-type="bibr">
<sup>175</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B176" ref-type="bibr">
<sup>176</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Emergency birth control</italic>
</td><td rowspan="1" colspan="1">ulipristal acetate</td><td rowspan="1" colspan="1">erythromycin</td><td rowspan="1" colspan="1">Inhibition of CYP3A4.</td><td rowspan="1" colspan="1">Avoid combination or adjust dose of substrates and closely monitor side effects.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B178" ref-type="bibr">
<sup>178</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Antimalarial agents</italic>
</td><td rowspan="1" colspan="1">halofantrine</td><td rowspan="1" colspan="1">tetracycline</td><td rowspan="1" colspan="1">Probably by CYP3A4 inhibition.</td><td rowspan="1" colspan="1">Avoid combination or perform TDM and adjust dose if needed.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B177" ref-type="bibr">
<sup>177</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Muscle relaxants</italic>
</td><td rowspan="1" colspan="1">tizanidine</td><td rowspan="1" colspan="1">ciprofloxacin</td><td rowspan="1" colspan="1">Inhibition of CYP1A2.</td><td rowspan="1" colspan="1">Avoid combination or perform TDM and adjust dose if needed.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B183" ref-type="bibr">
<sup>183</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Anti-diarrhoeals</italic>
</td><td rowspan="1" colspan="1">loperamide</td><td rowspan="1" colspan="1">TMP/SMX</td><td rowspan="1" colspan="1">Inhibition of CYP2C8.</td><td rowspan="1" colspan="1">Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B186" ref-type="bibr">
<sup>186</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Anaemia medications</italic>
</td><td rowspan="1" colspan="1">iron supplements</td><td rowspan="1" colspan="1">quinolone, tetracyclines</td><td rowspan="1" colspan="1">Complex formation.</td><td rowspan="1" colspan="1">Avoid co-administration or administer at interval of at least 2&#8201;h.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B212" ref-type="bibr">
<sup>212&#8211;220</sup>
</xref>
</td></tr><tr><td rowspan="2" colspan="1">
<italic toggle="yes">Other metal cations</italic>
</td><td rowspan="1" colspan="1">zinc sulfate</td><td rowspan="1" colspan="1">quinolone, tetracyclines</td><td rowspan="1" colspan="1">Complex formation.</td><td rowspan="1" colspan="1">Avoid co-administration or administer at interval of at least 2&#8201;h.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B144" ref-type="bibr">
<sup>144</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B188" ref-type="bibr">
<sup>188</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B189" ref-type="bibr">
<sup>189</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">calcium acetate, calcium carbonate, calcium polycarbophil, patiromer, lanthanum carbonate, sevelamer</td><td rowspan="1" colspan="1">quinolone, tetracyclines</td><td rowspan="1" colspan="1">Complex formation.</td><td rowspan="1" colspan="1">Administer at interval of at least 2&#8201;h.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B139" ref-type="bibr">
<sup>139</sup>
</xref>
<sup>,</sup>
<xref rid="dkz221-B190" ref-type="bibr">
<sup>190&#8211;193</sup>
</xref>
</td></tr><tr><td rowspan="3" colspan="1">
<italic toggle="yes">Other ABs</italic>
</td><td rowspan="1" colspan="1">linezolid</td><td rowspan="1" colspan="1">clarithromycin</td><td rowspan="1" colspan="1">Inhibition of P-gp.</td><td rowspan="1" colspan="1">Consider alternative or perform TDM and adjust dose if needed.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B196" ref-type="bibr">
<sup>196</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">dapsone</td><td rowspan="1" colspan="1">trimethoprim</td><td rowspan="1" colspan="1">Inhibition of CYP2C8.</td><td rowspan="1" colspan="1">Monitor side effects and if necessary adjust dose of substrate.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B187" ref-type="bibr">
<sup>187</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">neomycin</td><td rowspan="1" colspan="1">penicillin V</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Consider alternative or adjust dose of penicillin.</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">
<xref rid="dkz221-B221" ref-type="bibr">
<sup>221</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p>All detailed supporting information about each DDI is available in Tables <xref ref-type="supplementary-material" rid="sup1">S1 and S2</xref>.</p></fn><fn id="tblfn5"><p>OCT, organic cation transporter; OAT, organic anion transporter; MATE1, multidrug and toxin extrusion&#160;1; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not available yet.</p></fn><fn id="tblfn6"><label>a</label><p>1, strong interaction; 2, substantial interaction; 3, moderate interaction; 4, weak or no interaction.</p></fn></table-wrap-foot></table-wrap><p>We present a step-by-step approach to AB prescribing in COPD: (i) check whether co-morbidity is present; (ii) a quick overview of the AB and its interacting medication, possible interaction mechanism, level of interaction, and practical recommendations is provided in Table&#160;<xref rid="dkz221-T4" ref-type="table">4</xref>; and (iii) detailed explanation about related interacting mechanisms and recommendations for the management of related DDIs are provided in the main text.</p></sec><sec><title>Mechanisms of DDI</title><p>An AB can act as an inhibitor/inducer and/or a substrate, producing moderate to strong DDI with other co-administered medication. There are two scenarios: (i) the co-administered drug alters the pharmacokinetic parameters of the AB; and (ii) the AB influences the pharmacokinetic parameters of the co-administered medication. The main mechanisms of these DDIs are complex formation, inhibition/induction of drug-metabolizing enzymes and alteration of drug transporters (Table&#160;<xref rid="dkz221-T4" ref-type="table">4</xref>). The ability to inhibit CYP3A4 makes ABs prone to interaction with many different drugs as CYP3A4 metabolizes &gt;50% of clinically prescribed drugs.<xref rid="dkz221-B13" ref-type="bibr"><sup>13</sup></xref></p></sec><sec><title>Information structured according to drugs for comorbidities</title><p>The presentation of information on potential clinically significant DDIs with a moderate to strong level of interaction is according to the most frequent comorbidities that have been reported in COPD patients.<xref rid="dkz221-B8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="dkz221-B14" ref-type="bibr"><sup>14</sup></xref> Potential mechanisms of DDIs and actionable recommendations to manage the DDIs are provided in Table&#160;<xref rid="dkz221-T4" ref-type="table">4</xref>.</p><sec><title>Diabetes</title><p>Patients with COPD have a 50% higher risk of developing diabetes than persons without COPD.<xref rid="dkz221-B15" ref-type="bibr"><sup>15</sup></xref> Some antidiabetic drugs are substrates of enzymes such as CYP3A4 (glipizide, tolbutamide), CYP2C9 (glipizide, glyburide) and CYP2C8 (repaglinide), and substrates of drug transporter-like P-glycoprotein (P-gp) transporter (glipizide, glyburide).<xref rid="dkz221-B16" ref-type="bibr"><sup>16&#8211;26</sup></xref> ABs such as clarithromycin (CYP3A4 and P-gp inhibitor), trimethoprim/sulfamethoxazole (CYP2C8/2C9 inhibitor) and levofloxacin (P-gp inhibitor) may inhibit the function of these metabolic enzymes and transporters. These ABs can potentially increase the blood concentration of the antidiabetic agents mentioned above.<xref rid="dkz221-B16" ref-type="bibr"><sup>16&#8211;26</sup></xref> Consequently, patients may develop hypoglycaemia. Therefore, it is suggested that these combinations should be avoided by substituting a related AB or adjusting the dose of antidiabetic agents as well as monitoring the patients&#8217; blood glucose.</p></sec><sec><title>Heart and circulatory system diseases</title><sec><title>Antihypertensive agents</title><p>Hypertension is associated with COPD with a relative risk of 1.6.<xref rid="dkz221-B15" ref-type="bibr"><sup>15</sup></xref> Antihypertensive calcium channel blockers (CCBs) such as diltiazem and verapamil are CYP3A4 substrates.<xref rid="dkz221-B27" ref-type="bibr"><sup>27&#8211;29</sup></xref> Therefore, macrolides (CYP3A4 inhibitors) can enhance the pharmacological activity of CCBs.<xref rid="dkz221-B30" ref-type="bibr"><sup>30</sup></xref> Avoiding the combination by replacement of macrolides or CCBs with another group of drugs or adjusting the dose of CCBs while monitoring blood pressure is recommended. Erythromycin and clarithromycin are the most potent CYP3A4 inhibitors, while azithromycin and roxithromycin are weak inhibitors.<xref rid="dkz221-B30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="dkz221-B31" ref-type="bibr"><sup>31</sup></xref> Hence, if prescribing macrolides, choosing macrolides with minimal inhibitory capacity to be co-prescribed with CCBs may minimize the risk of DDI.</p><p>Spironolactone, a potassium-sparing diuretic, is used to lower blood pressure. Combination of spironolactone with trimethoprim/sulfamethoxazole may produce hyperkalaemia because both drugs can inhibit renal excretion of potassium.<xref rid="dkz221-B32" ref-type="bibr"><sup>32</sup></xref> Therefore, avoiding this combination (by selecting an alternative AB) or adjusting the dose of spironolactone and closely monitoring potassium plasma levels is strongly recommended.</p></sec><sec><title>Lipid-lowering drugs</title><p>Lipid metabolism problems are among the most prevalent comorbidities in COPD patients.<xref rid="dkz221-B14" ref-type="bibr"><sup>14</sup></xref> The main pharmacological approach to the management of blood cholesterol levels is statin therapy.<xref rid="dkz221-B33" ref-type="bibr"><sup>33</sup></xref> Some ABs increase the plasma concentration of statins by several mechanisms. Statins such as simvastatin and atorvastatin are biodegraded by CYP3A4.<xref rid="dkz221-B34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="dkz221-B35" ref-type="bibr"><sup>35</sup></xref> Therefore, potent CYP3A4 inhibitors (erythromycin and clarithromycin) increase the risk of statin-related side effects such as rhabdomyolysis.<xref rid="dkz221-B34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="dkz221-B35" ref-type="bibr"><sup>35</sup></xref> Other statins, such as rosuvastatin, pravastatin and fluvastatin, are not CYP3A4 substrates.<xref rid="dkz221-B36" ref-type="bibr"><sup>36</sup></xref> However, the hepatic clearance of these statins is facilitated by anion-transporting polypeptides.<xref rid="dkz221-B37" ref-type="bibr"><sup>37</sup></xref> These influx transporters facilitate the transport of statins from systemic blood to liver cells to be metabolized or subsequently delivered into the bile for elimination.<xref rid="dkz221-B37" ref-type="bibr"><sup>37</sup></xref> Clarithromycin and erythromycin have been reported to be inhibitors of these transporters.<xref rid="dkz221-B38" ref-type="bibr"><sup>38</sup></xref> Therefore, replacing erythromycin and clarithromycin with other ABs, temporarily stopping statins or adjusting the dose of statins while monitoring statin-related side effects is recommended.</p></sec><sec><title>Oral anticoagulants</title><p>Both coumarins and direct oral anticoagulants (DOACs) may interact with ABs. Multiple studies reported that DDIs between ABs and coumarins (warfarin, phenprocoumon, acenocoumarol) led to increased risks of haemorrhage.<xref rid="dkz221-B39" ref-type="bibr"><sup>39&#8211;58</sup></xref> Several interaction mechanisms were proposed.<xref rid="dkz221-B59" ref-type="bibr"><sup>59</sup></xref><sup>,</sup><xref rid="dkz221-B60" ref-type="bibr"><sup>60</sup></xref> One mechanism is by disruption of intestinal flora that synthesizes vitamin K, as many ABs could alter the balance of gut flora.<xref rid="dkz221-B59" ref-type="bibr"><sup>59</sup></xref> Another mechanism is that ABs (e.g. trimethoprim/sulfamethoxazole and macrolides) alter coumarin metabolism, which mainly involves CYP2C9 (trimethoprim/sulfamethoxazole) and CYP3A4 (macrolides).<xref rid="dkz221-B60" ref-type="bibr"><sup>60</sup></xref> Therefore, to choose alternative ABs or, if not possible, to monitor international normalized ratio (INR) values and adjust the dose of coumarins is recommended.</p><p>DOACs are regarded as a safe alternative to replace coumarins.<xref rid="dkz221-B61" ref-type="bibr"><sup>61</sup></xref> However, since some DOACs (edoxaban, rivaroxaban, dabigatran) are substrates of CYP3A4 and/or the P-gp transporter, their AUC values can be increased by ABs such as macrolides.<xref rid="dkz221-B62" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="dkz221-B63" ref-type="bibr"><sup>63</sup></xref> Therefore, when macrolides and DOACs are required in combination, careful monitoring of signs of bleeding is needed, and adjusting the dose of DOACs should be done if necessary.</p></sec><sec><title>Antiarrhythmic agents</title><p>Some antiarrhythmic agents, such as digoxin, quinidine, lignocaine and procainamide, potentially interact with ABs.<xref rid="dkz221-B64" ref-type="bibr"><sup>64&#8211;75</sup></xref> Quinidine and lignocaine are CYP3A4 substrates and therefore macrolides may inhibit their degradation and increase their bioavailabilities.<xref rid="dkz221-B64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="dkz221-B65" ref-type="bibr"><sup>65</sup></xref> The renal clearance of procainamide and digoxin is inhibited by trimethoprim.<xref rid="dkz221-B66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="dkz221-B67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="dkz221-B72" ref-type="bibr"><sup>72</sup></xref><sup>,</sup><xref rid="dkz221-B73" ref-type="bibr"><sup>73</sup></xref> The mechanism of interaction is inhibition of tubular secretion via inhibition of the renal organic cation transporter because they are substrates of the transporter.<xref rid="dkz221-B66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="dkz221-B67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="dkz221-B72" ref-type="bibr"><sup>72</sup></xref><sup>,</sup><xref rid="dkz221-B73" ref-type="bibr"><sup>73</sup></xref> Consequently, blood concentrations of these drugs are increased.<xref rid="dkz221-B66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="dkz221-B67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="dkz221-B72" ref-type="bibr"><sup>72</sup></xref><sup>,</sup><xref rid="dkz221-B73" ref-type="bibr"><sup>73</sup></xref> Digoxin is a substrate of the P-gp transporter.<xref rid="dkz221-B68" ref-type="bibr"><sup>68&#8211;71</sup></xref> Clarithromycin could elevate the AUC of digoxin, which may cause toxicities.<xref rid="dkz221-B68" ref-type="bibr"><sup>68&#8211;71</sup></xref> Since quinidine, lignocaine, digoxin and procainamide are drugs with an NTI, avoiding ABs that can lead to DDIs with these drugs is recommended.<xref rid="dkz221-B76" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="dkz221-B77" ref-type="bibr"><sup>77</sup></xref> However, if their co-prescription is necessary, therapeutic drug monitoring (TDM) of these antiarrhythmic agents is strongly recommended.<xref rid="dkz221-B77" ref-type="bibr"><sup>77</sup></xref></p></sec></sec></sec><sec><title>Respiratory diseases</title><sec><title>Medication for obstructive airways diseases</title><p>One of the most prevalent comorbidities in COPD is asthma.<xref rid="dkz221-B14" ref-type="bibr"><sup>14</sup></xref> Some anti-asthma drugs, such as methylprednisolone, montelukast, loratadine, roflumilast and theophylline, are substrates of CYP3A4 and/or the P-gp transporter and have been shown to interact with macrolides.<xref rid="dkz221-B78" ref-type="bibr"><sup>78&#8211;87</sup></xref> Hence, one might consider other ABs for combination with asthma drugs, or closely monitor patients, especially in the case of theophylline, which is an NTI drug.<xref rid="dkz221-B88" ref-type="bibr"><sup>88</sup></xref> As theophylline is also metabolized by CYP1A2,<xref rid="dkz221-B89" ref-type="bibr"><sup>89</sup></xref> ciprofloxacin (a CYP1A2 potent inhibitor) should be avoided.<xref rid="dkz221-B90" ref-type="bibr"><sup>90&#8211;97</sup></xref></p></sec><sec><title>Antimycobacterial agents</title><p>Tuberculosis and COPD share comparable risk factors and therefore can co-occur in individuals, particularly elderly patients.<xref rid="dkz221-B98" ref-type="bibr"><sup>98</sup></xref> Rifampicin and rifabutin (antimycobacterial agents) work as potent inducers of hepatic and intestinal CYP enzymes.<xref rid="dkz221-B99" ref-type="bibr"><sup>99</sup></xref> They can markedly reduce the activities of clarithromycin, doxycycline and trimethoprim/sulfamethoxazole by causing their rapid elimination.<xref rid="dkz221-B100" ref-type="bibr"><sup>100&#8211;104</sup></xref> Since rifampicin also exhibits other AB properties, such as activity against MRSA in combination with other drugs, rationalizing antimicrobial therapy should be considered accordingly.<xref rid="dkz221-B105" ref-type="bibr"><sup>105</sup></xref> Alternative ABs for treating COPD are also recommended to reduce the risk of treatment failures.</p><p>Moxifloxacin might be an alternative AB for clarithromycin, doxycycline and trimethoprim/sulfamethoxazole owing to its moderate or weak interaction with rifampicin.<xref rid="dkz221-B106" ref-type="bibr"><sup>106&#8211;109</sup></xref> Moxifloxacin is not metabolized by CYP450 and its interacting mechanisms with rifampicin might be facilitated by induction of other enzymes, such as uridine diphosphate-glucuronosyltransferases and sulfotransferases.<xref rid="dkz221-B106" ref-type="bibr"><sup>106&#8211;109</sup></xref></p><p>Rifabutin and rifampicin are CYP substrates. Rifabutin is a CYP3A4 substrate, and therefore macrolides may increase its serum concentration and enhance the risk of related ADR.<xref rid="dkz221-B101" ref-type="bibr"><sup>101</sup></xref><sup>,</sup><xref rid="dkz221-B110" ref-type="bibr"><sup>110</sup></xref><sup>,</sup><xref rid="dkz221-B111" ref-type="bibr"><sup>111</sup></xref> Another study reported that rifampicin concentrations in blood are moderately elevated by co-trimoxazole.<xref rid="dkz221-B104" ref-type="bibr"><sup>104</sup></xref> It was assumed that the interaction was facilitated by inhibition of mixed-function oxidases, which are responsible for metabolizing rifampicin.<xref rid="dkz221-B104" ref-type="bibr"><sup>104</sup></xref> Thus, considering alternative ABs or monitoring the clinical and biochemical parameters for rifampicin-related hepatotoxicity is suggested when rifampicin and co-trimoxazole are combined.</p><p>It should be mentioned that not all the drugs for atypical <italic toggle="yes">Mycobacterium</italic> spp. were included in this review because selection was limited to ABs that are used frequently among COPD patients. For drugs outside the scope of this review, other references (e.g. statements of product characteristics) need to be considered.</p></sec></sec><sec><title>Neurological disorders</title><sec><title>Anti-Parkinson&#8217;s drugs</title><p>Bromocriptine and cabergoline (dopamine agonists) are substrates of CYP3A4 and/or the P-gp transporter.<xref rid="dkz221-B112" ref-type="bibr"><sup>112</sup></xref><sup>,</sup><xref rid="dkz221-B113" ref-type="bibr"><sup>113</sup></xref> Co-prescription of these drugs with clarithromycin and erythromycin may produce major interactions and therefore might lead to toxicities.<xref rid="dkz221-B112" ref-type="bibr"><sup>112</sup></xref><sup>,</sup><xref rid="dkz221-B113" ref-type="bibr"><sup>113</sup></xref> Thus, avoiding such combinations is recommended. However, if this is not possible, adjusting the dose of these Parkinson&#8217;s medications and closely monitoring side effects are needed.</p></sec><sec><title>Antiepileptic drugs</title><p>Carbamazepine, phenytoin and phenobarbital can stimulate the activity of a variety of CYP (CYP1A2/2C9/3A4) and glucuronyl transferase enzymes, which results in multiple DDIs with other substrates for these enzymes.<xref rid="dkz221-B114" ref-type="bibr"><sup>114&#8211;116</sup></xref> Carbamazepine and phenytoin were reported to reduce the half-life of doxycycline by stimulating the hepatic metabolism of doxycycline.<xref rid="dkz221-B117" ref-type="bibr"><sup>117</sup></xref> It is suggested that an alternative AB should be considered or that the dose of antiepileptic drugs should be adjusted while monitoring the AB activity of doxycycline.</p><p>Carbamazepine and phenytoin are substrates of CYP1A2/3A4 and CYP2C8, respectively. A CYP1A2/3A4 inhibitor (ciprofloxacin) and a CYP2C8 inhibitor (trimethoprim) were reported to increase the bioavailability of carbamazepine and phenytoin, respectively.<xref rid="dkz221-B116" ref-type="bibr"><sup>116&#8211;119</sup></xref> Moreover, phenytoin is an NTI drug and therefore avoiding using trimethoprim concomitantly or performing TDM of phenytoin is recommended when this DDI is not avoidable.<xref rid="dkz221-B120" ref-type="bibr"><sup>120</sup></xref></p><p>Ciprofloxacin was reported to increase the AUC of carbamazepine by &gt;50%.<xref rid="dkz221-B118" ref-type="bibr"><sup>118</sup></xref> Although it is not clear whether carbamazepine can be considered to be an NTI drug, a rising carbamazepine plasma concentration because of this DDI needs special caution.<xref rid="dkz221-B121" ref-type="bibr"><sup>121</sup></xref> Dose adjustment and TDM of carbamazepine are suggested to diminish potential toxicities.</p></sec></sec><sec><title>Depression and psychiatric disorders</title><p>Depression and psychiatric disorders are common among COPD patients.<xref rid="dkz221-B14" ref-type="bibr"><sup>14</sup></xref> Some antidepressant (trazodone), anxiolytic (buspirone) and antipsychotic (quetiapine, and pimozide) drugs are CYP3A4 substrates and therefore might trigger clinically relevant DDIs with ABs.<xref rid="dkz221-B122" ref-type="bibr"><sup>122&#8211;125</sup></xref> Erythromycin and clarithromycin increased the AUCs of these drugs substantially.<xref rid="dkz221-B122" ref-type="bibr"><sup>122&#8211;125</sup></xref> Considering alternative ABs or adjusting the dose of substrates and monitoring related side effects is the way to control potential ADR.</p><p>CYP3A4 is also responsible for metabolizing diazepam, in addition to CYP2C19.<xref rid="dkz221-B126" ref-type="bibr"><sup>126</sup></xref> Ciprofloxacin was reported to decrease diazepam clearance moderately by inhibiting CYP3A4 activity.<xref rid="dkz221-B127" ref-type="bibr"><sup>127</sup></xref> Monitoring diazepam-related side effects can therefore be considered when this combination is prescribed.</p><p>Ciprofloxacin is also a potent CYP1A2 inhibitor.<xref rid="dkz221-B128" ref-type="bibr"><sup>128</sup></xref> Therefore, metabolism of an atypical antipsychotic, clozapine, a CYP1A2 substrate with an NTI, can be altered by ciprofloxacin, which produces a significant increase in clozapine serum concentration.<xref rid="dkz221-B129" ref-type="bibr"><sup>129</sup></xref><sup>,</sup><xref rid="dkz221-B130" ref-type="bibr"><sup>130</sup></xref> Replacing ciprofloxacin or TDM of clozapine is an option that can be chosen in managing this DDI.</p></sec><sec><title>Dyspepsia</title><p>Drugs containing metal cations (e.g. antacids, sucralfate and bismuth salts) produced chemical interactions with some ABs, such as oral tetracyclines (e.g. tetracycline, doxycycline) and fluoroquinolones (e.g. ciprofloxacin, moxifloxacin).<xref rid="dkz221-B131" ref-type="bibr"><sup>131&#8211;144</sup></xref> Tetracyclines have a strong tendency to form chelates due to their structural features, which include many chelation sites.<xref rid="dkz221-B145" ref-type="bibr"><sup>145</sup></xref> Meanwhile, fluoroquinolones have two main sites of metal chelation: 4-keto oxygen and 3-carboxylic acid groups.<xref rid="dkz221-B146" ref-type="bibr"><sup>146</sup></xref></p><p>The formation of metal ion chelation complexes decreases absorption of tetracycline and fluoroquinolones, and this reduced bioavailability may lead to ineffectiveness of these ABs.<xref rid="dkz221-B131" ref-type="bibr"><sup>131&#8211;144</sup></xref> Therefore, it is recommended that their combination should be avoided by replacing tetracyclines and fluoroquinolones with another AB, e.g. amoxicillin or amoxicillin/clavulanic acid. It was reported that antacids did not affect the bioavailability of amoxicillin and amoxicillin/clavulanic acid when they were co-administered.<xref rid="dkz221-B136" ref-type="bibr"><sup>136</sup></xref> If replacement of the AB is not possible, replacement of antacids, sucralfate or bismuth salts with a proton pump inhibitor (PPI) is also favoured. Another alternative is to separate administration by using quinolone or tetracycline at least 2&#8201;h before or 6&#8201;h after the dyspepsia drugs.</p><p>When considering a PPI, lansoprazole may not be the best alternative as it is partly metabolized by CYP3A4 and has been found to interact with clarithromycin.<xref rid="dkz221-B147" ref-type="bibr"><sup>147</sup></xref></p></sec><sec><title>HIV</title><p>HIV-positive patients have an &#8764;50% higher risk of developing COPD than HIV-negative patients.<xref rid="dkz221-B148" ref-type="bibr"><sup>148</sup></xref> Thus, the risk of co-prescriptions for treating these chronic conditions may also be high. A protease inhibitor (saquinavir) and NRTIs (didanosine and lamivudine) were found to clinically interact with ABs.<xref rid="dkz221-B149" ref-type="bibr"><sup>149&#8211;153</sup></xref></p><p>Didanosine is very acid sensitive, and therefore didanosine formulations are supplemented with buffering mixtures containing magnesium hydroxide, dihydroxyaluminium sodium carbonate and sodium citrate to prevent hydrolysis by gastric acid.<xref rid="dkz221-B149" ref-type="bibr"><sup>149</sup></xref> These metal ions may form chelation complexes with quinolones and reduce their serum concentration.<xref rid="dkz221-B149" ref-type="bibr"><sup>149</sup></xref><sup>,</sup><xref rid="dkz221-B150" ref-type="bibr"><sup>150</sup></xref> Two studies confirmed the didanosine and ciprofloxacin interaction, and recommended that when co-administration cannot be avoided, ciprofloxacin must be given at least 2&#8201;h before didanosine.<xref rid="dkz221-B149" ref-type="bibr"><sup>149</sup></xref><sup>,</sup><xref rid="dkz221-B150" ref-type="bibr"><sup>150</sup></xref></p><p>Trimethoprim/sulfamethoxazole may inhibit clearances of didanosine and lamivudine by competitively hindering their renal secretion.<xref rid="dkz221-B152" ref-type="bibr"><sup>152</sup></xref><sup>,</sup><xref rid="dkz221-B153" ref-type="bibr"><sup>153</sup></xref> Consequently, AUCs of didanosine and lamivudine are elevated moderately.<xref rid="dkz221-B152" ref-type="bibr"><sup>152</sup></xref><sup>,</sup><xref rid="dkz221-B153" ref-type="bibr"><sup>153</sup></xref> Monitoring of the presumed side effects should be performed.</p><p>Saquinavir is metabolized by CYP3A4 and the presence of erythromycin increased its AUC by almost 100%.<xref rid="dkz221-B151" ref-type="bibr"><sup>151</sup></xref> Choosing an alternative AB or adjusting the dose of saquinavir while monitoring toxicities can be considered as a means of managing this DDI.</p></sec><sec><title>Other potential clinically significant DDIs</title><p>Some other drugs that have indications for comorbidities in COPD patients were found to interact with ABs. Some individual drugs of different classes (e.g. voriconazole and vinorelbine) are metabolized by CYP3A4.<xref rid="dkz221-B154" ref-type="bibr"><sup>154&#8211;182</sup></xref> Therefore, their metabolism is interfered with by CYP3A4 inhibitors (macrolides).<xref rid="dkz221-B154" ref-type="bibr"><sup>154&#8211;182</sup></xref> Other drugs are CYP1A2 substrates (e.g. ropivacaine and tizanidine) and therefore potent inhibitors of CYP1A2, such as quinolones, significantly alter their metabolism and elevate their bioavailabilities.<xref rid="dkz221-B164" ref-type="bibr"><sup>164</sup></xref><sup>,</sup><xref rid="dkz221-B183" ref-type="bibr"><sup>183&#8211;185</sup></xref> Others are CYP2C8 substrates (e.g. loperamide for diarrhoea) and therefore trimethoprim (a potent CYP2C8 inhibitor) inhibits their clearance and increases their AUC values.<xref rid="dkz221-B186" ref-type="bibr"><sup>186</sup></xref><sup>,</sup><xref rid="dkz221-B187" ref-type="bibr"><sup>187</sup></xref> Some drugs containing metal cations (e.g. Fe, Zn, Ca) should be avoided or administered with a separation of at least 2&#8201;h from quinolones and tetracyclines.<xref rid="dkz221-B139" ref-type="bibr"><sup>139</sup></xref><sup>,</sup><xref rid="dkz221-B144" ref-type="bibr"><sup>144</sup></xref><sup>,</sup><xref rid="dkz221-B188" ref-type="bibr"><sup>188&#8211;193</sup></xref> Other interactions were facilitated by drug transporters. A uricosuric agent (probenecid) interacts moderately with ciprofloxacin via competitive inhibition of organic anion transporters in renal tubules.<xref rid="dkz221-B194" ref-type="bibr"><sup>194</sup></xref><sup>,</sup><xref rid="dkz221-B195" ref-type="bibr"><sup>195</sup></xref> Moreover, linezolid, which is a substrate of the P-gp transporter, can potentially produce clinically significant interaction with P-gp inhibitors (macrolides).<xref rid="dkz221-B196" ref-type="bibr"><sup>196</sup></xref></p><sec><title>DDIs related to NTIs</title><p>Some ABs may interact with NTI drugs and therefore can produce serious ADRs. The NTI drugs in this review include CYP3A4 substrates (theophylline, ketamine, everolimus, tacrolimus, halofantrine, lignocaine, quinidine, voriconazole, carbamazepine, warfarin, cyclosporine, colchicine, phenprocoumon/acenocoumarol); CYP1A2 substrates (theophylline, carbamazepine, clozapine, tizanidine); CYP2C9 substrates and drugs sensitive to alterations in the normal gut flora (warfarin, phenprocoumon/acenocoumarol); a CYP2C8 substrate (phenytoin); substrates of the P-gp transporter (digoxin, linezolid); and a substrate of the organic cation transporter (procainamide).<xref rid="dkz221-B76" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="dkz221-B77" ref-type="bibr"><sup>77</sup></xref><sup>,</sup><xref rid="dkz221-B88" ref-type="bibr"><sup>88</sup></xref><sup>,</sup><xref rid="dkz221-B120" ref-type="bibr"><sup>120</sup></xref><sup>,</sup><xref rid="dkz221-B197" ref-type="bibr"><sup>197</sup></xref></p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Included articles</title><p>This study outlines the possible DDIs related to frequently prescribed ABs in COPD patients from clinical and observational studies. We only included well-designed studies (&#8805;2 points) since they provide more valid evidence than studies without a control or comparison group (0 or 1 point). DDIs based on case reports or hypotheses may lead to unnecessary warnings if these are not confirmed by well-designed studies. One classic example of this point is ABs and oral contraceptive interactions; many cases of unintended pregnancies were reported after ABs were prescribed to women on oral contraceptives, which attracted much attention from health practitioners.<xref rid="dkz221-B198" ref-type="bibr"><sup>198</sup></xref><sup>,</sup><xref rid="dkz221-B199" ref-type="bibr"><sup>199</sup></xref> After scientific evidence from clinical and pharmacokinetic studies has consistently and repeatedly failed to support such interaction, the warning about DDIs between hormonal contraception and non-rifampicin ABs has finally been cancelled in related guidelines.<xref rid="dkz221-B199" ref-type="bibr"><sup>199</sup></xref></p></sec><sec><title>Mechanisms of DDI</title><p>A DDI of potential clinical significance between an AB and a co-administered medication may occur in two situations: (i) the co-administered drug influences the absorption, distribution, metabolism and elimination (ADME) of the AB; and (ii) the AB influences the ADME of the co-administered medication. When the AB acted as a substrate, some co-administered drugs reduced the blood concentration of the AB and led to failure of the AB treatment to reduce COPD exacerbations. Other co-administered drugs increased the blood concentration of the AB, which could result in the termination of AB use because of an ADR, and therefore acted against the control of infection. Acting as inhibitors, ABs could also increase the blood concentrations of co-administered drugs, which may also produce an ADR and lead to termination of co-administered drugs, and therefore may lead to failure of treatment of comorbidities. Thus, DDIs related to ABs may hinder effective infection control and exacerbation management among COPD patients as well as treatment of comorbidities in COPD.</p></sec><sec><title>Comorbidities among COPD patients</title><p>The impact of comorbidities on quality of life in COPD patients is well reported; however, potential drug interactions between drugs for these comorbidities and ABs used for COPD have received little specific attention. From this review, we found that many drugs (e.g. those used for heart and circulatory system diseases) should not be co-administered with related ABs, and other actions are necessary, such as dose adjustment, choosing an alternative drug and monitoring ADRs. These drug interactions may not only influence treatment options for clinical practitioners but also influence treatment effects for both COPD and comorbidities.</p><p>Information collected in this review can be used as input to improve the sensitivity and specificity of DDI alert systems. Moreover, this study may also be attractive for researchers in this field who may take into account the availability of high-quality studies when evaluating the evidence for many potential interactions.</p></sec><sec><title>Special warning for NTI drugs</title><p>We found that some NTI drugs might potentially interact with ABs. Because of the narrow separation between effective and toxic dosing of these drugs, a small alteration of their pharmacokinetic parameters can produce fatal consequences.<xref rid="dkz221-B88" ref-type="bibr"><sup>88</sup></xref><sup>,</sup><xref rid="dkz221-B120" ref-type="bibr"><sup>120</sup></xref> Therefore, combination with particular ABs that have an ability to inhibit their clearance pathways should be avoided if possible. However, if the benefits of combination outweigh the potential side effects, dose adjustment and performing TDM of the NTI drugs are strongly recommended.</p></sec><sec><title>Limitations</title><p>Some limitations of this review are worth mentioning. First, although we reviewed a significant part of the literature, we did not include all sources that might indicate relevant DDIs, such as case reports, summary of product characteristics and theoretical hypotheses. As a result, we did not find some DDIs that are considered serious and clinically highly relevant, such as QT-interval prolonging interactions for combinations of macrolides with other QT-prolonging drugs or the risk of pseudotumour cerebri in the case of combinations of doxycycline with vitamin A analogues.<xref rid="dkz221-B200" ref-type="bibr"><sup>200</sup></xref><sup>,</sup><xref rid="dkz221-B201" ref-type="bibr"><sup>201</sup></xref> Such interactions are commonly found as case reports, as it is unethical to design studies to confirm these serious risks in clinical studies. However, for some DDIs it is possible to study the clinical manifestation of a potential DDI in an observational study using real-world drug utilization data.<xref rid="dkz221-B202" ref-type="bibr"><sup>202</sup></xref> Secondly, selection of the ABs included in this review was based on their frequent use in COPD and therefore information for other ABs used for COPD comorbidities, such as atypical <italic toggle="yes">Mycobacterium</italic> spp., is limited, and this may restrict the scope of application of this review. Thirdly, due to limited comparative analyses for several specific DDIs included in this review, it may be difficult to make recommendations for a specific situation. Our classification of DDI levels only offers a general consideration. The specific impact of a DDI is determined by many variables, such as different doses and formulations and the comorbidities of patients. Therefore, case-by-case analysis is important in clinical practice and a drug interaction handbook such as <italic toggle="yes">Stockley&#8217;s Drug Interactions</italic><xref rid="dkz221-B203" ref-type="bibr"><sup>203</sup></xref> further expands on these issues.</p></sec></sec><sec><title>Conclusions</title><p>Clinically significant DDIs related to ABs may involve a wide range of indicated drugs to treat comorbidities in COPD. Clinicians should pay attention to these drug interactions when prescribing ABs in order to reduce the frequency and severity of exacerbations in COPD patients and take necessary actions to ensure therapeutic effect and safety of patients. This study may contribute to better prescribing of ABs to COPD patients with comorbidities where potentially interacting drug combinations may be used. Furthermore, the information may highlight gaps in scientific knowledge about potential adverse effects from DDIs.</p></sec><sec><title>Funding</title><p>This study was supported by internal funding. Y. W. received a scholarship (file number: 201506010259) from China Scholarship Council (CSC; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.csc.edu.cn/">http://www.csc.edu.cn/</ext-link>) for her PhD studies at the University of Groningen, Groningen, the Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></sec><sec><title>Transparency declarations</title><p>None to declare.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1" position="float" orientation="portrait"><label>dkz221_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dkz221_supplementary_data.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list id="REF1"><title>References</title><ref id="dkz221-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogelmeier</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Criner</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></name></person-group><etal>et al</etal><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary</article-title>. <source>Am J Respir Crit Care Med</source><year>2017</year>; <volume>195</volume>: <fpage>557</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">28128970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201701-0218PP</pub-id></mixed-citation></ref><ref id="dkz221-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decramer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Janssens</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Miravitlles</surname><given-names>M.</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease</article-title>. <source>Lancet</source><year>2012</year>; <volume>379</volume>: <fpage>1341</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">22314182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(11)60968-9</pub-id><pub-id pub-id-type="pmcid">PMC7172377</pub-id></mixed-citation></ref><ref id="dkz221-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sethi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>TF.</given-names></name></person-group><article-title>Infection in the pathogenesis and course of chronic obstructive pulmonary disease</article-title>. <source>N Engl J Med</source><year>2008</year>; <volume>359</volume>: <fpage>2355</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">19038881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra0800353</pub-id></mixed-citation></ref><ref id="dkz221-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vollenweider</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Jarrett</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Steurer-Stey</surname><given-names>CA</given-names></name></person-group><etal>et al</etal><article-title>Antibiotics for exacerbations of chronic obstructive pulmonary disease</article-title>. <source>Cochrane Database Syst Rev</source><year>2012</year>; issue <volume>12</volume>: <fpage>CD010257.</fpage><pub-id pub-id-type="pmid">23235687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD010257</pub-id></mixed-citation></ref><ref id="dkz221-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herath</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Poole</surname><given-names>P.</given-names></name></person-group><article-title>Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD</article-title>). <source>Cochrane Database Syst Rev</source><year>2013</year>; issue <volume>12</volume>: <fpage>CD009764</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD009764.pub2</pub-id><pub-id pub-id-type="pmid">24288145</pub-id></mixed-citation></ref><ref id="dkz221-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zijp</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Bahar</surname><given-names>MA</given-names></name></person-group><etal>et al</etal><article-title>Effects of prophylactic antibiotics on patients with stable COPD: a systematic review and meta-analysis of randomized controlled trials</article-title>. <source>J Antimicrob Chemother</source><year>2018</year>; <volume>73</volume>: <fpage>3231</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">30189002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dky326</pub-id></mixed-citation></ref><ref id="dkz221-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wedzicha</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Calverley</surname><given-names>PMA</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>RK</given-names></name></person-group><etal>et al</etal><article-title>Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline</article-title>. <source>Eur Respir J</source><year>2017</year>; <volume>50</volume>: <fpage>1602265.</fpage><pub-id pub-id-type="pmid">28889106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.02265-2016</pub-id></mixed-citation></ref><ref id="dkz221-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chetty</surname><given-names>U</given-names></name>, <name name-style="western"><surname>McLean</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Morrison</surname><given-names>D</given-names></name></person-group><etal>et al</etal><article-title>Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care</article-title>. <source>Br J Gen Pract</source><year>2017</year>; <volume>67</volume>: <fpage>e321</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28450344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3399/bjgp17X690605</pub-id><pub-id pub-id-type="pmcid">PMC5409435</pub-id></mixed-citation></ref><ref id="dkz221-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangoni</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>SH.</given-names></name></person-group><article-title>Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications</article-title>. <source>Br J Clin Pharmacol</source><year>2004</year>; <volume>57</volume>: <fpage>6</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">14678335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.02007.x</pub-id><pub-id pub-id-type="pmcid">PMC1884408</pub-id></mixed-citation></ref><ref id="dkz221-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahar</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Hak</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bos</surname><given-names>JH</given-names></name></person-group><etal>et al</etal><article-title>The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug&#8211;drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly</article-title>. <source>Pharmacoepidemiol Drug Saf</source><year>2017</year>; <volume>26</volume>: <fpage>752</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">28345306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pds.4200</pub-id></mixed-citation></ref><ref id="dkz221-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Roon</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Flikweert</surname><given-names>S</given-names></name>, <name name-style="western"><surname>le Comte</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>Clinical relevance of drug&#8211;drug interactions: a structured assessment procedure</article-title>. <source>Drug Saf</source><year>2005</year>; <volume>28</volume>: <fpage>1131</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">16329715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00002018-200528120-00007</pub-id></mixed-citation></ref><ref id="dkz221-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahar</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Setiawan</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hak</surname><given-names>E</given-names></name></person-group><etal>et al</etal><article-title>Pharmacogenetics of drug&#8211;drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6</article-title>. <source>Pharmacogenomics</source><year>2017</year>; <volume>18</volume>: <fpage>701</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">28480783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/pgs-2017-0194</pub-id></mixed-citation></ref><ref id="dkz221-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name></person-group><etal>et al</etal><article-title>Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4</article-title>. <source>Ther Clin Risk Manag</source><year>2005</year>; <volume>1</volume>: <fpage>3</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">18360537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/tcrm.1.1.3.53600</pub-id><pub-id pub-id-type="pmcid">PMC1661603</pub-id></mixed-citation></ref><ref id="dkz221-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Divo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cote</surname><given-names>C</given-names></name>, <name name-style="western"><surname>de Torres</surname><given-names>JP</given-names></name></person-group><etal>et al</etal><article-title>Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease</article-title>. <source>Am J Respir Crit Care Med</source><year>2012</year>; <volume>186</volume>: <fpage>155</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">22561964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201201-0034OC</pub-id></mixed-citation></ref><ref id="dkz221-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mannino</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Thorn</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Swensen</surname><given-names>A</given-names></name></person-group><etal>et al</etal><article-title>Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD</article-title>. <source>Eur Respir J</source><year>2008</year>; <volume>32</volume>: <fpage>962</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18579551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/09031936.00012408</pub-id></mixed-citation></ref><ref id="dkz221-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schelleman</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bilker</surname><given-names>WB</given-names></name>, <name name-style="western"><surname>Brensinger</surname><given-names>CM</given-names></name></person-group><etal>et al</etal><article-title>Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide</article-title>. <source>Clin Pharmacol Ther</source><year>2010</year>; <volume>88</volume>: <fpage>214</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">20592722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2010.74</pub-id><pub-id pub-id-type="pmcid">PMC2908202</pub-id></mixed-citation></ref><ref id="dkz221-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lilja</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fredrikson</surname><given-names>H</given-names></name></person-group><etal>et al</etal><article-title>Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide</article-title>. <source>Br J Clin Pharmacol</source><year>2007</year>; <volume>63</volume>: <fpage>732</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">17223855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2006.02836.x</pub-id><pub-id pub-id-type="pmcid">PMC2000598</pub-id></mixed-citation></ref><ref id="dkz221-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Kuo</surname><given-names>YF</given-names></name></person-group><etal>et al</etal><article-title>Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use</article-title>. <source>J Gerontol A Biol Sci Med Sci</source><year>2015</year>; <volume>70</volume>: <fpage>247</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">24858839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glu072</pub-id><pub-id pub-id-type="pmcid">PMC4311183</pub-id></mixed-citation></ref><ref id="dkz221-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kradjan</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Witt</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Opheim</surname><given-names>KE</given-names></name></person-group><etal>et al</etal><article-title>Lack of interaction between glipizide and co-trimoxazole</article-title>. <source>J Clin Pharmacol</source><year>1994</year>; <volume>34</volume>: <fpage>997</fpage>&#8211;<lpage>1002</lpage>.<pub-id pub-id-type="pmid">7836551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1994.tb01972.x</pub-id></mixed-citation></ref><ref id="dkz221-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayasagar</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Dixit</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Kishan</surname><given-names>V</given-names></name></person-group><etal>et al</etal><article-title>Effect of clarithromycin on the pharmacokinetics of tolbutamide</article-title>. <source>Drug Metabol Drug Interact</source><year>2000</year>; <volume>16</volume>: <fpage>207</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">11116754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/dmdi.2000.16.3.207</pub-id></mixed-citation></ref><ref id="dkz221-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wing</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Miners</surname><given-names>JO.</given-names></name></person-group><article-title>Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition</article-title>. <source>Br J Clin Pharmacol</source><year>1985</year>; <volume>20</volume>: <fpage>482</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">3878154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1985.tb05102.x</pub-id><pub-id pub-id-type="pmcid">PMC1400714</pub-id></mixed-citation></ref><ref id="dkz221-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Kivisto</surname><given-names>KT.</given-names></name></person-group><article-title>The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide</article-title>. <source>Clin Pharmacol Ther</source><year>2001</year>; <volume>70</volume>: <fpage>58</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">11452245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2001.116511</pub-id></mixed-citation></ref><ref id="dkz221-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kajosaari</surname><given-names>LI</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects</article-title>. <source>Br J Clin Pharmacol</source><year>2004</year>; <volume>57</volume>: <fpage>441</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15025742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.02027.x</pub-id><pub-id pub-id-type="pmcid">PMC1884466</pub-id></mixed-citation></ref><ref id="dkz221-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hruska</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Amico</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Langaee</surname><given-names>TY</given-names></name></person-group><etal>et al</etal><article-title>The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects</article-title>. <source>Br J Clin Pharmacol</source><year>2005</year>; <volume>59</volume>: <fpage>70</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">15606443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2005.02263.x</pub-id><pub-id pub-id-type="pmcid">PMC1884957</pub-id></mixed-citation></ref><ref id="dkz221-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grun</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kiessling</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name></person-group><etal>et al</etal><article-title>Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters</article-title>. <source>Br J Clin Pharmacol</source><year>2013</year>; <volume>76</volume>: <fpage>787</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">23305245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.12079</pub-id><pub-id pub-id-type="pmcid">PMC3853537</pub-id></mixed-citation></ref><ref id="dkz221-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Pontones</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Renner</surname><given-names>B</given-names></name></person-group><etal>et al</etal><article-title>N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction</article-title>. <source>Eur J Clin Pharmacol</source><year>2015</year>; <volume>71</volume>: <fpage>85</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">25552403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-014-1770-2</pub-id></mixed-citation></ref><ref id="dkz221-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Gomes</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mamdani</surname><given-names>MM</given-names></name></person-group><etal>et al</etal><article-title>The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers</article-title>. <source>CMAJ</source><year>2011</year>; <volume>183</volume>: <fpage>303</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21242274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.100702</pub-id><pub-id pub-id-type="pmcid">PMC3042440</pub-id></mixed-citation></ref><ref id="dkz221-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fleet</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Bailey</surname><given-names>DG</given-names></name></person-group><etal>et al</etal><article-title>Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury</article-title>. <source>JAMA</source><year>2013</year>; <volume>310</volume>: <fpage>2544</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">24346990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2013.282426</pub-id></mixed-citation></ref><ref id="dkz221-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraser</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Shariff</surname><given-names>SZ</given-names></name>, <name name-style="western"><surname>McArthur</surname><given-names>E</given-names></name></person-group><etal>et al</etal><article-title>Calcium channel blocker-clarithromycin drug interaction did not increase the risk of nonvertebral fracture: a population-based study</article-title>. <source>Ann Pharmacother</source><year>2015</year>; <volume>49</volume>: <fpage>185</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25429094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1060028014561474</pub-id></mixed-citation></ref><ref id="dkz221-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westphal</surname><given-names>JF.</given-names></name></person-group><article-title>Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin</article-title>. <source>Br J Clin Pharmacol</source><year>2000</year>; <volume>50</volume>: <fpage>285</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">11012550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2000.00261.x</pub-id><pub-id pub-id-type="pmcid">PMC2015000</pub-id></mixed-citation></ref><ref id="dkz221-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shimada</surname><given-names>T.</given-names></name></person-group><article-title>Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6&#946;-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin</article-title>. <source>Drug Metab Dispos</source><year>1998</year>; <volume>26</volume>: <fpage>1053</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">9806945</pub-id></mixed-citation></ref><ref id="dkz221-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antoniou</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hollands</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Macdonald</surname><given-names>EM</given-names></name></person-group><etal>et al</etal><article-title>Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone</article-title>. <source>CMAJ</source><year>2015</year>; <volume>187</volume>: <fpage>E138</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">25646289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.140816</pub-id><pub-id pub-id-type="pmcid">PMC4347789</pub-id></mixed-citation></ref><ref id="dkz221-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parhofer</surname><given-names>KG.</given-names></name></person-group><article-title>The treatment of disorders of lipid metabolism</article-title>. <source>Dtsch Arztebl Int</source><year>2016</year>; <volume>113</volume>: <fpage>261</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27151464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3238/arztebl.2016.0261</pub-id><pub-id pub-id-type="pmcid">PMC4860871</pub-id></mixed-citation></ref><ref id="dkz221-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantola</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kivisto</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ.</given-names></name></person-group><article-title>Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations</article-title>. <source>Clin Pharmacol Ther</source><year>1998</year>; <volume>64</volume>: <fpage>177</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">9728898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(98)90151-5</pub-id></mixed-citation></ref><ref id="dkz221-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amsden</surname><given-names>GW</given-names></name>, <name name-style="western"><surname>Kuye</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>GC.</given-names></name></person-group><article-title>A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers</article-title>. <source>J Clin Pharmacol</source><year>2002</year>; <volume>42</volume>: <fpage>444</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11936570</pub-id></mixed-citation></ref><ref id="dkz221-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>DQ</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>R</given-names></name>, <name name-style="western"><surname>McArthur</surname><given-names>E</given-names></name></person-group><etal>et al</etal><article-title>Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4</article-title>. <source>CMAJ</source><year>2015</year>; <volume>187</volume>: <fpage>174</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">25534598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.140950</pub-id><pub-id pub-id-type="pmcid">PMC4330139</pub-id></mixed-citation></ref><ref id="dkz221-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalliokoski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Niemi</surname><given-names>M.</given-names></name></person-group><article-title>Impact of OATP transporters on pharmacokinetics</article-title>. <source>Br J Pharmacol</source><year>2009</year>; <volume>158</volume>: <fpage>693</fpage>&#8211;<lpage>705</lpage>.<pub-id pub-id-type="pmid">19785645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.2009.00430.x</pub-id><pub-id pub-id-type="pmcid">PMC2765590</pub-id></mixed-citation></ref><ref id="dkz221-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seithel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Eberl</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Singer</surname><given-names>K</given-names></name></person-group><etal>et al</etal><article-title>The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3</article-title>. <source>Drug Metab Dispos</source><year>2007</year>; <volume>35</volume>: <fpage>779</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">17296622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.106.014407</pub-id></mixed-citation></ref><ref id="dkz221-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glasheen</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Fugit</surname><given-names>RV</given-names></name>, <name name-style="western"><surname>Prochazka</surname><given-names>AV.</given-names></name></person-group><article-title>The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens</article-title>. <source>J Gen Intern Med</source><year>2005</year>; <volume>20</volume>: <fpage>653</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">16050864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1525-1497.2005.0136.x</pub-id><pub-id pub-id-type="pmcid">PMC1490169</pub-id></mixed-citation></ref><ref id="dkz221-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Zeringue</surname><given-names>A</given-names></name>, <name name-style="western"><surname>McDonald</surname><given-names>JR.</given-names></name></person-group><article-title>Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans</article-title>. <source>Am J Med</source><year>2014</year>; <volume>127</volume>: <fpage>657.</fpage><pub-id pub-id-type="pmid">24657899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2014.01.044</pub-id><pub-id pub-id-type="pmcid">PMC4116816</pub-id></mixed-citation></ref><ref id="dkz221-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghaswalla</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Harpe</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Tassone</surname><given-names>D</given-names></name></person-group><etal>et al</etal><article-title>Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic</article-title>. <source>Am J Geriatr Pharmacother</source><year>2012</year>; <volume>10</volume>: <fpage>352</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">23089199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjopharm.2012.09.006</pub-id></mixed-citation></ref><ref id="dkz221-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mergenhagen</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Olbrych</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Mattappallil</surname><given-names>A</given-names></name></person-group><etal>et al</etal><article-title>Effect of azithromycin on anticoagulation-related outcomes in geriatric patients receiving warfarin</article-title>. <source>Clin Ther</source><year>2013</year>; <volume>35</volume>: <fpage>425</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">23453406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2013.02.012</pub-id></mixed-citation></ref><ref id="dkz221-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCall</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>HG</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Jones</surname><given-names>AD.</given-names></name></person-group><article-title>Determination of the lack of a drug interaction between azithromycin and warfarin</article-title>. <source>Pharmacotherapy</source><year>2004</year>; <volume>24</volume>: <fpage>188</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">14998219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1592/phco.24.2.188.33148</pub-id></mixed-citation></ref><ref id="dkz221-B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>HD</given-names></name>, <name name-style="western"><surname>Juurlink</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Mamdani</surname><given-names>MM</given-names></name></person-group><etal>et al</etal><article-title>Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study</article-title>. <source>Arch Intern Med</source><year>2010</year>; <volume>170</volume>: <fpage>617</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">20386005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinternmed.2010.37</pub-id></mixed-citation></ref><ref id="dkz221-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Washington</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Hughes</surname><given-names>NC</given-names></name></person-group><etal>et al</etal><article-title>Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics</article-title>. <source>J Clin Pharmacol</source><year>2007</year>; <volume>47</volume>: <fpage>1320</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17724088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270007305504</pub-id></mixed-citation></ref><ref id="dkz221-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Israel</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Stotka</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rock</surname><given-names>W</given-names></name></person-group><etal>et al</etal><article-title>Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin</article-title>. <source>Clin Infect Dis</source><year>1996</year>; <volume>22</volume>: <fpage>251</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">8838180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/clinids/22.2.251</pub-id></mixed-citation></ref><ref id="dkz221-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianco</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Bussey</surname><given-names>HI</given-names></name>, <name name-style="western"><surname>Farnett</surname><given-names>LE</given-names></name></person-group><etal>et al</etal><article-title>Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation</article-title>. <source>Pharmacotherapy</source><year>1992</year>; <volume>12</volume>: <fpage>435</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">1492006</pub-id></mixed-citation></ref><ref id="dkz221-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Aziz</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>AK</given-names></name></person-group><etal>et al</etal><article-title>Warfarin-drug interactions: an emphasis on influence of polypharmacy and high doses of amoxicillin/clavulanate</article-title>. <source>J Clin Pharmacol</source><year>2016</year>; <volume>56</volume>: <fpage>39</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">26138877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.583</pub-id></mixed-citation></ref><ref id="dkz221-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schelleman</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bilker</surname><given-names>WB</given-names></name>, <name name-style="western"><surname>Brensinger</surname><given-names>CM</given-names></name></person-group><etal>et al</etal><article-title>Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding</article-title>. <source>Clin Pharmacol Ther</source><year>2008</year>; <volume>84</volume>: <fpage>581</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18685566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.150</pub-id><pub-id pub-id-type="pmcid">PMC2574587</pub-id></mixed-citation></ref><ref id="dkz221-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baillargeon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>YL</given-names></name></person-group><etal>et al</etal><article-title>Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults</article-title>. <source>Am J Med</source><year>2012</year>; <volume>125</volume>: <fpage>183</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22269622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2011.08.014</pub-id><pub-id pub-id-type="pmcid">PMC3712345</pub-id></mixed-citation></ref><ref id="dkz221-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Reilly</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Motley</surname><given-names>CH.</given-names></name></person-group><article-title>Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans</article-title>. <source>Ann Intern Med</source><year>1979</year>; <volume>91</volume>: <fpage>34</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">464451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-91-1-34</pub-id></mixed-citation></ref><ref id="dkz221-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercadal Orfila</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gracia Garcia</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Leiva Badosa</surname><given-names>E</given-names></name></person-group><etal>et al</etal><article-title>Retrospective assessment of potential interaction between levofloxacin and warfarin</article-title>. <source>Pharm World Sci</source><year>2009</year>; <volume>31</volume>: <fpage>224</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19067226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11096-008-9265-9</pub-id></mixed-citation></ref><ref id="dkz221-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fowler</surname><given-names>C</given-names></name></person-group><etal>et al</etal><article-title>Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers</article-title>. <source>J Clin Pharmacol</source><year>1996</year>; <volume>36</volume>: <fpage>1072</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">8973996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/009127009603601111</pub-id></mixed-citation></ref><ref id="dkz221-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stroud</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>Mamdami</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Kopp</surname><given-names>A</given-names></name></person-group><etal>et al</etal><article-title>The safety of levofloxacin in elderly patients on warfarin</article-title>. <source>Am J Med</source><year>2005</year>; <volume>118</volume>: <fpage>1417.</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2005.06.066</pub-id><pub-id pub-id-type="pmid">16378802</pub-id></mixed-citation></ref><ref id="dkz221-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beest</surname><given-names>P-v</given-names></name>, <name name-style="western"><surname>van Meegen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rosendaal</surname><given-names>FR</given-names></name></person-group><etal>et al</etal><article-title>Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs</article-title>. <source>Clin Pharmacol Ther</source><year>2001</year>; <volume>69</volume>: <fpage>451</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11406743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2001.115723</pub-id></mixed-citation></ref><ref id="dkz221-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jobski</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Behr</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Garbe</surname><given-names>E.</given-names></name></person-group><article-title>Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case&#8211;control study in a large population-based German database</article-title>. <source>Eur J Clin Pharmacol</source><year>2011</year>; <volume>67</volume>: <fpage>941</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">21452031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-011-1031-6</pub-id></mixed-citation></ref><ref id="dkz221-B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbas</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ihle</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Harder</surname><given-names>S</given-names></name></person-group><etal>et al</etal><article-title>Risk of bleeding and antibiotic use in patients receiving continuous phenprocoumon therapy. A case&#8211;control study nested in a large insurance- and population-based German cohort</article-title>. <source>Thromb Haemost</source><year>2014</year>; <volume>111</volume>: <fpage>912</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">24429904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1160/TH13-09-0723</pub-id></mixed-citation></ref><ref id="dkz221-B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beest</surname><given-names>P-v</given-names></name>, <name name-style="western"><surname>Koerselman</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Herings</surname><given-names>RM.</given-names></name></person-group><article-title>Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants</article-title>. <source>J Thromb Haemost</source><year>2008</year>; <volume>6</volume>: <fpage>284</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">18031295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1538-7836.2008.02844.x</pub-id></mixed-citation></ref><ref id="dkz221-B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juurlink</surname><given-names>DN.</given-names></name></person-group><article-title>Drug interactions with warfarin: what clinicians need to know</article-title>. <source>CMAJ</source><year>2007</year>; <volume>177</volume>: <fpage>369</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">17698826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.070946</pub-id><pub-id pub-id-type="pmcid">PMC1942100</pub-id></mixed-citation></ref><ref id="dkz221-B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ufer</surname><given-names>M.</given-names></name></person-group><article-title>Comparative pharmacokinetics of vitamin K antagonists&#8212;warfarin, phenprocoumon and acenocoumarol</article-title>. <source>Clin Pharmacokinet</source><year>2005</year>; <volume>44</volume>: <fpage>1227</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">16372822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200544120-00003</pub-id></mixed-citation></ref><ref id="dkz221-B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thachil</surname><given-names>J.</given-names></name></person-group><article-title>The newer direct oral anticoagulants: a practical guide</article-title>. <source>Clin Med (Lond)</source><year>2014</year>; <volume>14</volume>: <fpage>165</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">24715128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7861/clinmedicine.14-2-165</pub-id><pub-id pub-id-type="pmcid">PMC4953288</pub-id></mixed-citation></ref><ref id="dkz221-B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parasrampuria</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Mendell</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>Edoxaban drug&#8211;drug interactions with ketoconazole, erythromycin, and cyclosporine</article-title>. <source>Br J Clin Pharmacol</source><year>2016</year>; <volume>82</volume>: <fpage>1591</fpage>&#8211;<lpage>600</lpage>.<pub-id pub-id-type="pmid">27530188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13092</pub-id><pub-id pub-id-type="pmcid">PMC5099547</pub-id></mixed-citation></ref><ref id="dkz221-B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouin-Thibault</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Delavenne</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Blanchard</surname><given-names>A</given-names></name></person-group><etal>et al</etal><article-title>Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin</article-title>. <source>J Thromb Haemost</source><year>2017</year>; <volume>15</volume>: <fpage>273</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">27893182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.13577</pub-id></mixed-citation></ref><ref id="dkz221-B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damkier</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Brosen</surname><given-names>K.</given-names></name></person-group><article-title>Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine</article-title>. <source>Br J Clin Pharmacol</source><year>1999</year>; <volume>48</volume>: <fpage>829</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">10594487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.1999.00099.x</pub-id><pub-id pub-id-type="pmcid">PMC2014310</pub-id></mixed-citation></ref><ref id="dkz221-B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isohanni</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Olkkola</surname><given-names>KT.</given-names></name></person-group><article-title>Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine</article-title>. <source>Pharmacol Toxicol</source><year>1999</year>; <volume>84</volume>: <fpage>143</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">10193676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0773.1999.tb00890.x</pub-id></mixed-citation></ref><ref id="dkz221-B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosoglou</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rocci</surname><given-names>ML</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Vlasses</surname><given-names>PH.</given-names></name></person-group><article-title>Trimethoprim alters the disposition of procainamide and N-acetylprocainamide</article-title>. <source>Clin Pharmacol Ther</source><year>1988</year>; <volume>44</volume>: <fpage>467</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">2458879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1988.181</pub-id></mixed-citation></ref><ref id="dkz221-B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlasses</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Kosoglou</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chase</surname><given-names>SL</given-names></name></person-group><etal>et al</etal><article-title>Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide</article-title>. <source>Arch Intern Med</source><year>1989</year>; <volume>149</volume>: <fpage>1350</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">2471472</pub-id></mixed-citation></ref><ref id="dkz221-B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zapater</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Reus</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tello</surname><given-names>A</given-names></name></person-group><etal>et al</etal><article-title>A prospective study of the clarithromycin-digoxin interaction in elderly patients</article-title>. <source>J Antimicrob Chemother</source><year>2002</year>; <volume>50</volume>: <fpage>601</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">12356809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkf176</pub-id></mixed-citation></ref><ref id="dkz221-B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>CY</given-names></name></person-group><etal>et al</etal><article-title>Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study</article-title>. <source>Eur J Clin Pharmacol</source><year>2009</year>; <volume>65</volume>: <fpage>1237</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">19655133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-009-0698-4</pub-id></mixed-citation></ref><ref id="dkz221-B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ueno</surname><given-names>K</given-names></name></person-group><etal>et al</etal><article-title>Effect of clarithromycin on steady-state digoxin concentrations</article-title>. <source>Ann Pharmacother</source><year>2003</year>; <volume>37</volume>: <fpage>178</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">12549942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/106002800303700202</pub-id></mixed-citation></ref><ref id="dkz221-B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rengelshausen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Goggelmann</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name></person-group><etal>et al</etal><article-title>Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction</article-title>. <source>Br J Clin Pharmacol</source><year>2003</year>; <volume>56</volume>: <fpage>32</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">12848773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.01824.x</pub-id><pub-id pub-id-type="pmcid">PMC1884337</pub-id></mixed-citation></ref><ref id="dkz221-B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kastrup</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bartram</surname><given-names>R</given-names></name></person-group><etal>et al</etal><article-title>Digoxin-trimethoprim interaction</article-title>. <source>Acta Med Scand</source><year>1985</year>; <volume>217</volume>: <fpage>423</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">4013832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.0954-6820.1985.tb02718.x</pub-id></mixed-citation></ref><ref id="dkz221-B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauer</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Lill</surname><given-names>JS</given-names></name></person-group><etal>et al</etal><article-title>Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances</article-title>. <source>Antimicrob Agents Chemother</source><year>2005</year>; <volume>49</volume>: <fpage>1649</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">15793163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.49.4.1649-1651.2005</pub-id><pub-id pub-id-type="pmcid">PMC1068590</pub-id></mixed-citation></ref><ref id="dkz221-B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Griener</surname><given-names>J</given-names></name></person-group><etal>et al</etal><article-title>Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide</article-title>. <source>J Clin Pharmacol</source><year>1996</year>; <volume>36</volume>: <fpage>85</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">8932548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1996.tb04156.x</pub-id></mixed-citation></ref><ref id="dkz221-B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ujhelyi</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Bottorff</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Schur</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>Aging effects on the organic base transporter and stereoselective renal clearance</article-title>. <source>Clin Pharmacol Ther</source><year>1997</year>; <volume>62</volume>: <fpage>117</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">9284847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(97)90059-X</pub-id></mixed-citation></ref><ref id="dkz221-B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raebel</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Andrade</surname><given-names>SE</given-names></name></person-group><etal>et al</etal><article-title>Monitoring of drugs with a narrow therapeutic range in ambulatory care</article-title>. <source>Am J Manag Care</source><year>2006</year>; <volume>12</volume>: <fpage>268</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">16686584</pub-id></mixed-citation></ref><ref id="dkz221-B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>K.</given-names></name></person-group><article-title>Therapeutic drug monitoring: antiarrhythmic drugs</article-title>. <source>Br J Clin Pharmacol</source><year>2001</year>; <volume>52</volume>: <fpage>21</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2001.0520s1021.x</pub-id><pub-id pub-id-type="pmcid">PMC2014627</pub-id><pub-id pub-id-type="pmid">11564050</pub-id></mixed-citation></ref><ref id="dkz221-B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fost</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>DY</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>RJ</given-names></name></person-group><etal>et al</etal><article-title>Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy</article-title>. <source>J Allergy Clin Immunol</source><year>1999</year>; <volume>103</volume>: <fpage>1031</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">10359882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0091-6749(99)70175-2</pub-id></mixed-citation></ref><ref id="dkz221-B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hegazy</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Mabrouk</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Elsisi</surname><given-names>AE</given-names></name></person-group><etal>et al</etal><article-title>Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers</article-title>. <source>Eur J Clin Pharmacol</source><year>2012</year>; <volume>68</volume>: <fpage>1275</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">22392555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-012-1239-0</pub-id></mixed-citation></ref><ref id="dkz221-B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Branigan</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Robbins</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Cady</surname><given-names>WJ</given-names></name></person-group><etal>et al</etal><article-title>The effects of erythromycin on the absorption and disposition of kinetics of theophylline</article-title>. <source>Eur J Clin Pharmacol</source><year>1981</year>; <volume>21</volume>: <fpage>115</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">7341279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00637511</pub-id></mixed-citation></ref><ref id="dkz221-B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reisz</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pingleton</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Melethil</surname><given-names>S</given-names></name></person-group><etal>et al</etal><article-title>The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis</article-title>. <source>Am Rev Respir Dis</source><year>1983</year>; <volume>127</volume>: <fpage>581</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">6846940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/arrd.1983.127.5.581</pub-id></mixed-citation></ref><ref id="dkz221-B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Wing</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Weinberger</surname><given-names>MM</given-names></name></person-group><etal>et al</etal><article-title>Effect of erythromycin on theophylline kinetics</article-title>. <source>J Allergy Clin Immunol</source><year>1981</year>; <volume>68</volume>: <fpage>427</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">7031111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0091-6749(81)90196-2</pub-id></mixed-citation></ref><ref id="dkz221-B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>May</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Jarboe</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Ellenburg</surname><given-names>DT</given-names></name></person-group><etal>et al</etal><article-title>The effects of erythromycin on theophylline elimination in normal males</article-title>. <source>J Clin Pharmacol</source><year>1982</year>; <volume>22</volume>: <fpage>125</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">7068935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1982.tb02659.x</pub-id></mixed-citation></ref><ref id="dkz221-B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maddux</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Leeds</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Organek</surname><given-names>HW</given-names></name></person-group><etal>et al</etal><article-title>The effect of erythromycin on theophylline pharmacokinetics at steady-state</article-title>. <source>Chest</source><year>1982</year>; <volume>81</volume>: <fpage>563</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">7042226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.81.5.563</pub-id></mixed-citation></ref><ref id="dkz221-B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeifer</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Friedman</surname><given-names>P.</given-names></name></person-group><article-title>Effects of three antibiotics on theophylline kinetics</article-title>. <source>Clin Pharmacol Ther</source><year>1979</year>; <volume>26</volume>: <fpage>36</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">445960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt197926136</pub-id></mixed-citation></ref><ref id="dkz221-B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carr</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Edmonds</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>H</given-names></name></person-group><etal>et al</etal><article-title>Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration</article-title>. <source>Antimicrob Agents Chemother</source><year>1998</year>; <volume>42</volume>: <fpage>1176</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">9593146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.42.5.1176</pub-id><pub-id pub-id-type="pmcid">PMC105769</pub-id></mixed-citation></ref><ref id="dkz221-B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brannan</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Reidenberg</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Radwanski</surname><given-names>E</given-names></name></person-group><etal>et al</etal><article-title>Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations</article-title>. <source>Clin Pharmacol Ther</source><year>1995</year>; <volume>58</volume>: <fpage>269</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">7554700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0009-9236(95)90243-0</pub-id></mixed-citation></ref><ref id="dkz221-B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blix</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Viktil</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Moger</surname><given-names>TA</given-names></name></person-group><etal>et al</etal><article-title>Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients</article-title>. <source>Pharm Pract (Granada)</source><year>2010</year>; <volume>8</volume>: <fpage>50</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">25152793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4321/s1886-36552010000100006</pub-id><pub-id pub-id-type="pmcid">PMC4140577</pub-id></mixed-citation></ref><ref id="dkz221-B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Freiburghaus</surname><given-names>A</given-names></name></person-group><etal>et al</etal><article-title>Metabolism of theophylline by cDNA-expressed human cytochromes P-450</article-title>. <source>Br J Clin Pharmacol</source><year>1995</year>; <volume>39</volume>: <fpage>321</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">7619675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1995.tb04455.x</pub-id><pub-id pub-id-type="pmcid">PMC1365010</pub-id></mixed-citation></ref><ref id="dkz221-B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nix</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>DeVito</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Whitbread</surname><given-names>MA</given-names></name></person-group><etal>et al</etal><article-title>Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green</article-title>. <source>J Antimicrob Chemother</source><year>1987</year>; <volume>19</volume>: <fpage>263</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">3571046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/19.2.263</pub-id></mixed-citation></ref><ref id="dkz221-B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijnands</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Vree</surname><given-names>TB</given-names></name>, <name name-style="western"><surname>van Herwaarden</surname><given-names>CL.</given-names></name></person-group><article-title>The influence of quinolone derivatives on theophylline clearance</article-title>. <source>Br J Clin Pharmacol</source><year>1986</year>; <volume>22</volume>: <fpage>677</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">3567014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1986.tb02957.x</pub-id><pub-id pub-id-type="pmcid">PMC1401213</pub-id></mixed-citation></ref><ref id="dkz221-B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loi</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Parker</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Cusack</surname><given-names>BJ</given-names></name></person-group><etal>et al</etal><article-title>Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers</article-title>. <source>Br J Clin Pharmacol</source><year>1993</year>; <volume>36</volume>: <fpage>195</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="pmid">9114903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1993.tb04216.x</pub-id><pub-id pub-id-type="pmcid">PMC1364637</pub-id></mixed-citation></ref><ref id="dkz221-B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Begg</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Atkinson</surname><given-names>HC</given-names></name></person-group><etal>et al</etal><article-title>Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline</article-title>. <source>Br J Clin Pharmacol</source><year>1990</year>; <volume>29</volume>: <fpage>491</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">2328197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1990.tb03669.x</pub-id><pub-id pub-id-type="pmcid">PMC1380121</pub-id></mixed-citation></ref><ref id="dkz221-B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Casabar</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Adair</surname><given-names>CG</given-names></name></person-group><etal>et al</etal><article-title>Effect of quinolone antimicrobials on theophylline pharmacokinetics</article-title>. <source>J Clin Pharmacol</source><year>1989</year>; <volume>29</volume>: <fpage>650</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">2760258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1989.tb03394.x</pub-id></mixed-citation></ref><ref id="dkz221-B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raoof</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wollschlager</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>FA.</given-names></name></person-group><article-title>Ciprofloxacin increases serum levels of theophylline</article-title>. <source>Am J Med</source><year>1987</year>; <volume>82</volume>: <fpage>115</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">3578320</pub-id></mixed-citation></ref><ref id="dkz221-B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antoniou</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gomes</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mamdani</surname><given-names>MM</given-names></name></person-group><etal>et al</etal><article-title>Ciprofloxacin-induced theophylline toxicity: a population-based study</article-title>. <source>Eur J Clin Pharmacol</source><year>2011</year>; <volume>67</volume>: <fpage>521</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">21234553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-010-0985-0</pub-id></mixed-citation></ref><ref id="dkz221-B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batty</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Ilett</surname><given-names>KF</given-names></name></person-group><etal>et al</etal><article-title>The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects</article-title>. <source>Br J Clin Pharmacol</source><year>1995</year>; <volume>39</volume>: <fpage>305</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">7619673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1995.tb04453.x</pub-id><pub-id pub-id-type="pmcid">PMC1365008</pub-id></mixed-citation></ref><ref id="dkz221-B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inghammar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ekbom</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Engstr&#246;m</surname><given-names>G</given-names></name></person-group><etal>et al</etal><article-title>COPD and the risk of tuberculosis&#8212;a population-based cohort study</article-title>. <source>PLoS One</source><year>2010</year>; <volume>5</volume>: <fpage>e10138.</fpage><pub-id pub-id-type="pmid">20405056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0010138</pub-id><pub-id pub-id-type="pmcid">PMC2854124</pub-id></mixed-citation></ref><ref id="dkz221-B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baciewicz</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Chrisman</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Finch</surname><given-names>CK</given-names></name></person-group><etal>et al</etal><article-title>Update on rifampin, rifabutin, and rifapentine drug interactions</article-title>. <source>Curr Med Res Opin</source><year>2013</year>; <volume>29</volume>: <fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1185/03007995.2012.747952</pub-id><pub-id pub-id-type="pmid">23136913</pub-id></mixed-citation></ref><ref id="dkz221-B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>RJ</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Brown</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Griffith</surname><given-names>DE</given-names></name></person-group><etal>et al</etal><article-title>Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for <italic toggle="yes">Mycobacterium avium-M. intracellulare</italic> infection</article-title>. <source>J Infect Dis</source><year>1995</year>; <volume>171</volume>: <fpage>747</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">7876634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/171.3.747</pub-id></mixed-citation></ref><ref id="dkz221-B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hafner</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bethel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Power</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers</article-title>. <source>Antimicrob Agents Chemother</source><year>1998</year>; <volume>42</volume>: <fpage>631</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9517944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.42.3.631</pub-id><pub-id pub-id-type="pmcid">PMC105510</pub-id></mixed-citation></ref><ref id="dkz221-B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colmenero</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Fernandez-Gallardo</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Agundez</surname><given-names>JA</given-names></name></person-group><etal>et al</etal><article-title>Possible implications of doxycycline-rifampin interaction for treatment of brucellosis</article-title>. <source>Antimicrob Agents Chemother</source><year>1994</year>; <volume>38</volume>: <fpage>2798</fpage>&#8211;<lpage>802</lpage>.<pub-id pub-id-type="pmid">7695265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.38.12.2798</pub-id><pub-id pub-id-type="pmcid">PMC188288</pub-id></mixed-citation></ref><ref id="dkz221-B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winter</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Trapnell</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Slattery</surname><given-names>JT</given-names></name></person-group><etal>et al</etal><article-title>The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283)</article-title>. <source>Clin Pharmacol Ther</source><year>2004</year>; <volume>76</volume>: <fpage>313</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">15470330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2004.06.002</pub-id></mixed-citation></ref><ref id="dkz221-B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatia</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Uppal</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Malhi</surname><given-names>R</given-names></name></person-group><etal>et al</etal><article-title>Drug-interaction between rifampicin and cotrimoxazole in patients with tuberculosis</article-title>. <source>Hum Exp Toxicol</source><year>1991</year>; <volume>10</volume>: <fpage>419</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">1687853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/096032719101000609</pub-id></mixed-citation></ref><ref id="dkz221-B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garske</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kidd</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gan</surname><given-names>R</given-names></name></person-group><etal>et al</etal><article-title>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection</article-title>. <source>J Hosp Infect</source><year>2004</year>; <volume>56</volume>: <fpage>208</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">15003669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhin.2003.12.003</pub-id></mixed-citation></ref><ref id="dkz221-B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiner</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Burman</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>CC</given-names></name></person-group><etal>et al</etal><article-title>Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin</article-title>. <source>Antimicrob Agents Chemother</source><year>2007</year>; <volume>51</volume>: <fpage>2861</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17517835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01621-06</pub-id><pub-id pub-id-type="pmcid">PMC1932492</pub-id></mixed-citation></ref><ref id="dkz221-B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nijland</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Ruslami</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Suroto</surname><given-names>AJ</given-names></name></person-group><etal>et al</etal><article-title>Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis</article-title>. <source>Clin Infect Dis</source><year>2007</year>; <volume>45</volume>: <fpage>1001</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">17879915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/521894</pub-id></mixed-citation></ref><ref id="dkz221-B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manika</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chatzika</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Papaioannou</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study</article-title>. <source>Int J Tuberc Lung Dis</source><year>2015</year>; <volume>19</volume>: <fpage>1383</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26467592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5588/ijtld.14.0935</pub-id></mixed-citation></ref><ref id="dkz221-B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naidoo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chirehwa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>McIlleron</surname><given-names>H</given-names></name></person-group><etal>et al</etal><article-title>Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB</article-title>. <source>J Antimicrob Chemother</source><year>2017</year>; <volume>72</volume>: <fpage>1441</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28175315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkx004</pub-id><pub-id pub-id-type="pmcid">PMC5890691</pub-id></mixed-citation></ref><ref id="dkz221-B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apseloff</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Foulds</surname><given-names>G</given-names></name>, <name name-style="western"><surname>LaBoy-Goral</surname><given-names>L</given-names></name></person-group><etal>et al</etal><article-title>Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers</article-title>. <source>Eur Respir J</source><year>1998</year>; <volume>38</volume>: <fpage>830</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">9753212</pub-id></mixed-citation></ref><ref id="dkz221-B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Polis</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>G</given-names></name></person-group><etal>et al</etal><article-title>Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics</article-title>. <source>J Clin Pharmacol</source><year>2000</year>; <volume>44</volume>: <fpage>2170</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.44.8.2170-2172.2000</pub-id><pub-id pub-id-type="pmcid">PMC90031</pub-id><pub-id pub-id-type="pmid">10898693</pub-id></mixed-citation></ref><ref id="dkz221-B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>MV</given-names></name>, <name name-style="western"><surname>Berchou</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Kareti</surname><given-names>D</given-names></name></person-group><etal>et al</etal><article-title>Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine</article-title>. <source>Clin Pharmacol Ther</source><year>1990</year>; <volume>47</volume>: <fpage>694</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">2357864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1990.95</pub-id></mixed-citation></ref><ref id="dkz221-B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakatsuka</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nagai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yabe</surname><given-names>H</given-names></name></person-group><etal>et al</etal><article-title>Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson&#8217;s disease</article-title>. <source>J Pharmacol Sci</source><year>2006</year>; <volume>100</volume>: <fpage>59</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">16410677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1254/jphs.fp0050711</pub-id></mixed-citation></ref><ref id="dkz221-B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perucca</surname><given-names>E.</given-names></name></person-group><article-title>Clinically relevant drug interactions with antiepileptic drugs</article-title>. <source>Br J Clin Pharmacol</source><year>2006</year>; <volume>61</volume>: <fpage>246</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">16487217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2005.02529.x</pub-id><pub-id pub-id-type="pmcid">PMC1885026</pub-id></mixed-citation></ref><ref id="dkz221-B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Penttila</surname><given-names>O.</given-names></name></person-group><article-title>Interaction between doxycycline and barbiturates</article-title>. <source>Br Med J</source><year>1974</year>; <volume>1</volume>: <fpage>535</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">4817187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.1.5907.535</pub-id><pub-id pub-id-type="pmcid">PMC1633645</pub-id></mixed-citation></ref><ref id="dkz221-B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Kampmann</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Siersbaek-Nielsen</surname><given-names>K</given-names></name></person-group><etal>et al</etal><article-title>The effect of different sulfonamides on phenytoin metabolism in man</article-title>. <source>Acta Med Scand Suppl</source><year>1979</year>; <volume>624</volume>: <fpage>106</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">284708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.0954-6820.1979.tb00729.x</pub-id></mixed-citation></ref><ref id="dkz221-B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penttila</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Aho</surname><given-names>K</given-names></name></person-group><etal>et al</etal><article-title>Interaction between doxycycline and some antiepileptic drugs</article-title>. <source>Br Med J</source><year>1974</year>; <volume>2</volume>: <fpage>470</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">4600204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.2.5917.470</pub-id><pub-id pub-id-type="pmcid">PMC1610633</pub-id></mixed-citation></ref><ref id="dkz221-B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahzadi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Javed</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Aslam</surname><given-names>B</given-names></name></person-group><etal>et al</etal><article-title>Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers</article-title>. <source>Pak J Pharm Sci</source><year>2011</year>; <volume>24</volume>: <fpage>63</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21190921</pub-id></mixed-citation></ref><ref id="dkz221-B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antoniou</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gomes</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mamdani</surname><given-names>MM</given-names></name></person-group><etal>et al</etal><article-title>Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study</article-title>. <source>Br J Clin Pharmacol</source><year>2011</year>; <volume>71</volume>: <fpage>544</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21395647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2010.03866.x</pub-id><pub-id pub-id-type="pmcid">PMC3080642</pub-id></mixed-citation></ref><ref id="dkz221-B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenberg</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Melloni</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H</given-names></name></person-group><etal>et al</etal><article-title>Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach</article-title>. <source>Clin Neuropharmacol</source><year>2016</year>; <volume>39</volume>: <fpage>232</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">27428884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNF.0000000000000172</pub-id><pub-id pub-id-type="pmcid">PMC5026556</pub-id></mixed-citation></ref><ref id="dkz221-B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bialer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rene'H</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Perucca</surname><given-names>E.</given-names></name></person-group><article-title>Does carbamazepine have a narrow therapeutic plasma concentration range?</article-title><source>Ther Drug Monit</source><year>1998</year>; <volume>20</volume>: <fpage>56</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9485555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-199802000-00010</pub-id></mixed-citation></ref><ref id="dkz221-B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>KY</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>ZN</given-names></name></person-group><etal>et al</etal><article-title>Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia</article-title>. <source>Eur J Clin Pharmacol</source><year>2005</year>; <volume>60</volume>: <fpage>791</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">15599502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-004-0853-x</pub-id></mixed-citation></ref><ref id="dkz221-B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desta</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Kerbusch</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Flockhart</surname><given-names>DA.</given-names></name></person-group><article-title>Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)</article-title>. <source>Clin Pharmacol Ther</source><year>1999</year>; <volume>65</volume>: <fpage>10</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">9951426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(99)70117-7</pub-id></mixed-citation></ref><ref id="dkz221-B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farkas</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Volak</surname><given-names>LP</given-names></name>, <name name-style="western"><surname>Harmatz</surname><given-names>JS</given-names></name></person-group><etal>et al</etal><article-title>Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem</article-title>. <source>Clin Pharmacol Ther</source><year>2009</year>; <volume>85</volume>: <fpage>644</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">19242403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.293</pub-id></mixed-citation></ref><ref id="dkz221-B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kivisto</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Lamberg</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Kantola</surname><given-names>T</given-names></name></person-group><etal>et al</etal><article-title>Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole</article-title>. <source>Clin Pharmacol Ther</source><year>1997</year>; <volume>62</volume>: <fpage>348</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">9333111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(97)90038-2</pub-id></mixed-citation></ref><ref id="dkz221-B126"><label>126</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dean</surname><given-names>L.</given-names></name></person-group><chapter-title>Diazepam therapy and CYP2C19 genotype</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Pratt</surname><given-names>V</given-names></name>, <name name-style="western"><surname>McLeod</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rubinstein</surname><given-names>W</given-names></name></person-group><etal>et al</etal>, eds. <source>Medical Genetics Summaries</source>. 
<publisher-loc>Bethesda, USA</publisher-loc>: 
<publisher-name>National Center for Biotechnology Information</publisher-name>, <year>2012</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK379740/">https://www.ncbi.nlm.nih.gov/books/NBK379740/</ext-link>.<pub-id pub-id-type="pmid">28520370</pub-id></mixed-citation></ref><ref id="dkz221-B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamali</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>C.</given-names></name></person-group><article-title>The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers</article-title>. <source>Eur J Clin Pharmacol</source><year>1993</year>; <volume>44</volume>: <fpage>365</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">8513847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00316474</pub-id></mixed-citation></ref><ref id="dkz221-B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuhr</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Anders</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Mahr</surname><given-names>G</given-names></name></person-group><etal>et al</etal><article-title>Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro</article-title>. <source>Antimicrob Agents Chemother</source><year>1992</year>; <volume>36</volume>: <fpage>942</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">1510417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.36.5.942</pub-id><pub-id pub-id-type="pmcid">PMC188773</pub-id></mixed-citation></ref><ref id="dkz221-B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raaska</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ.</given-names></name></person-group><article-title>Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia</article-title>. <source>Eur J Clin Pharmacol</source><year>2000</year>; <volume>56</volume>: <fpage>585</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11151749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280000192</pub-id></mixed-citation></ref><ref id="dkz221-B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Proctor</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cummings</surname><given-names>MA</given-names></name></person-group><etal>et al</etal><article-title>Ciprofloxacin and clozapine: a potentially fatal but underappreciated interaction</article-title>. <source>Case Rep Psychiatry</source><year>2016</year>; <volume>2016</volume>: <fpage>5606098.</fpage><pub-id pub-id-type="pmid">27872784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/5606098</pub-id><pub-id pub-id-type="pmcid">PMC5107233</pub-id></mixed-citation></ref><ref id="dkz221-B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nix</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Wilton</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Ronald</surname><given-names>B</given-names></name></person-group><etal>et al</etal><article-title>Inhibition of norfloxacin absorption by antacids</article-title>. <source>Antimicrob Agents Chemother</source><year>1990</year>; <volume>34</volume>: <fpage>432</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">2334155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.34.3.432</pub-id><pub-id pub-id-type="pmcid">PMC171610</pub-id></mixed-citation></ref><ref id="dkz221-B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garty</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hurwitz</surname><given-names>A.</given-names></name></person-group><article-title>Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline</article-title>. <source>Clin Pharmacol Ther</source><year>1980</year>; <volume>28</volume>: <fpage>203</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">7398187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1980.151</pub-id></mixed-citation></ref><ref id="dkz221-B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Slooten</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Nix</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Wilton</surname><given-names>JH</given-names></name></person-group><etal>et al</etal><article-title>Combined use of ciprofloxacin and sucralfate</article-title>. <source>DICP</source><year>1991</year>; <volume>25</volume>: <fpage>578</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">1877263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/106002809102500601</pub-id></mixed-citation></ref><ref id="dkz221-B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parpia</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Nix</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Hejmanowski</surname><given-names>LG</given-names></name></person-group><etal>et al</etal><article-title>Sucralfate reduces the gastrointestinal absorption of norfloxacin</article-title>. <source>Antimicrob Agents Chemother</source><year>1989</year>; <volume>33</volume>: <fpage>99</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="pmid">2712548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.33.1.99</pub-id><pub-id pub-id-type="pmcid">PMC171428</pub-id></mixed-citation></ref><ref id="dkz221-B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehto</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kivisto</surname><given-names>KT.</given-names></name></person-group><article-title>Effect of sucralfate on absorption of norfloxacin and ofloxacin</article-title>. <source>Antimicrob Agents Chemother</source><year>1994</year>; <volume>38</volume>: <fpage>248</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">8192452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.38.2.248</pub-id><pub-id pub-id-type="pmcid">PMC284435</pub-id></mixed-citation></ref><ref id="dkz221-B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deppermann</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Lode</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hoffken</surname><given-names>G</given-names></name></person-group><etal>et al</etal><article-title>Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid</article-title>. <source>Antimicrob Agents Chemother</source><year>1989</year>; <volume>33</volume>: <fpage>1901</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">2610502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.33.11.1901</pub-id><pub-id pub-id-type="pmcid">PMC172785</pub-id></mixed-citation></ref><ref id="dkz221-B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nix</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Watson</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Lener</surname><given-names>ME</given-names></name></person-group><etal>et al</etal><article-title>Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin</article-title>. <source>Clin Pharmacol Ther</source><year>1989</year>; <volume>46</volume>: <fpage>700</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">2598571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1989.207</pub-id></mixed-citation></ref><ref id="dkz221-B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stass</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bottcher</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Ochmann</surname><given-names>K.</given-names></name></person-group><article-title>Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers</article-title>. <source>Clin Pharmacokinet</source><year>2001</year>; <volume>40 Suppl 1</volume>: <fpage>39</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">11352441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200140001-00006</pub-id></mixed-citation></ref><ref id="dkz221-B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Lasseter</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Noe</surname><given-names>AJ</given-names></name></person-group><etal>et al</etal><article-title>Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin</article-title>. <source>Antimicrob Agents Chemother</source><year>1992</year>; <volume>36</volume>: <fpage>830</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">1503446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.36.4.830</pub-id><pub-id pub-id-type="pmcid">PMC189440</pub-id></mixed-citation></ref><ref id="dkz221-B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motoya</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shimozono</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name></person-group><etal>et al</etal><article-title>Effects of milk and aluminum hydroxide on the absorption of norfloxacin, ciprofloxacin and tosufloxacin in healthy volunteers</article-title>. <source>J Appl Ther</source><year>1997</year>; <volume>1</volume>: <fpage>213</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="dkz221-B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>VX</given-names></name>, <name name-style="western"><surname>Nix</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Gillikin</surname><given-names>S</given-names></name></person-group><etal>et al</etal><article-title>Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline</article-title>. <source>Antimicrob Agents Chemother</source><year>1989</year>; <volume>33</volume>: <fpage>434</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">2729939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.33.4.434</pub-id><pub-id pub-id-type="pmcid">PMC172455</pub-id></mixed-citation></ref><ref id="dkz221-B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nix</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Watson</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Handy</surname><given-names>L</given-names></name></person-group><etal>et al</etal><article-title>The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin</article-title>. <source>Pharmacotherapy</source><year>1989</year>; <volume>9</volume>: <fpage>377</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">2616352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1875-9114.1989.tb04152.x</pub-id></mixed-citation></ref><ref id="dkz221-B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albert</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Welch</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>DeSante</surname><given-names>KA</given-names></name></person-group><etal>et al</etal><article-title>Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture</article-title>. <source>J Pharm Sci</source><year>1979</year>; <volume>68</volume>: <fpage>586</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">435335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.2600680518</pub-id></mixed-citation></ref><ref id="dkz221-B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mapp</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>McCarthy</surname><given-names>TJ.</given-names></name></person-group><article-title>The effect of zinc sulphate and of bicitropeptide on tetracycline absorption</article-title>. <source>S Afr Med J</source><year>1976</year>; <volume>50</volume>: <fpage>1829</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">996681</pub-id></mixed-citation></ref><ref id="dkz221-B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chopra</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>M.</given-names></name></person-group><article-title>Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance</article-title>. <source>Microbiol Mol Biol Rev</source><year>2001</year>; <volume>65</volume>: <fpage>232.</fpage><pub-id pub-id-type="pmid">11381101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MMBR.65.2.232-260.2001</pub-id><pub-id pub-id-type="pmcid">PMC99026</pub-id></mixed-citation></ref><ref id="dkz221-B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamberi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nakashima</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ogawa</surname><given-names>K</given-names></name></person-group><etal>et al</etal><article-title>The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin</article-title>. <source>Br J Clin Pharmacol</source><year>2000</year>; <volume>49</volume>: <fpage>98</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="pmid">10671902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2000.00118.x</pub-id><pub-id pub-id-type="pmcid">PMC2014908</pub-id></mixed-citation></ref><ref id="dkz221-B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tada</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yasui-Furukori</surname><given-names>N</given-names></name></person-group><etal>et al</etal><article-title>Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes</article-title>. <source>Chirality</source><year>2005</year>; <volume>17</volume>: <fpage>338</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">15856433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chir.20159</pub-id></mixed-citation></ref><ref id="dkz221-B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crothers</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Butt</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Gibert</surname><given-names>CL</given-names></name></person-group><etal>et al</etal><article-title>Increased COPD among HIV-positive compared to HIV-negative veterans</article-title>. <source>Chest</source><year>2006</year>; <volume>130</volume>: <fpage>1326</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">17099007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.130.5.1326</pub-id></mixed-citation></ref><ref id="dkz221-B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahai</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gallicano</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Oliveras</surname><given-names>L</given-names></name></person-group><etal>et al</etal><article-title>Cations in the didanosine tablet reduce ciprofloxacin bioavailability</article-title>. <source>Clin Pharmacol Ther</source><year>1993</year>; <volume>53</volume>: <fpage>292</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">8453847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1993.24</pub-id></mixed-citation></ref><ref id="dkz221-B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knupp</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Barbhaiya</surname><given-names>RH.</given-names></name></person-group><article-title>A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic</article-title>. <source>Biopharm Drug Dispos</source><year>1997</year>; <volume>18</volume>: <fpage>65</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">9008270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1099-081x(199701)18:1&lt;65::aid-bdd13&gt;3.0.co;2-r</pub-id></mixed-citation></ref><ref id="dkz221-B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grub</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bryson</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Goggin</surname><given-names>T</given-names></name></person-group><etal>et al</etal><article-title>The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients</article-title>. <source>Eur J Clin Pharmacol</source><year>2001</year>; <volume>57</volume>: <fpage>115</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">11417442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280100277</pub-id></mixed-citation></ref><ref id="dkz221-B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srinivas</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Knupp</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Batteiger</surname><given-names>B</given-names></name></person-group><etal>et al</etal><article-title>A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients</article-title>. <source>Br J Clin Pharmacol</source><year>1996</year>; <volume>41</volume>: <fpage>207</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">8866920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1996.tb00184.x</pub-id></mixed-citation></ref><ref id="dkz221-B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Yuen</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Raasch</surname><given-names>RH</given-names></name></person-group><etal>et al</etal><article-title>Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole</article-title>. <source>Clin Pharmacol Ther</source><year>1996</year>; <volume>59</volume>: <fpage>550</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">8646826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(96)90183-6</pub-id></mixed-citation></ref><ref id="dkz221-B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>WH</given-names></name></person-group><etal>et al</etal><article-title>Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism</article-title>. <source>Eur J Clin Pharmacol</source><year>2010</year>; <volume>66</volume>: <fpage>1131</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">20669013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-010-0869-3</pub-id><pub-id pub-id-type="pmcid">PMC2957581</pub-id></mixed-citation></ref><ref id="dkz221-B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sriwiriyajan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Samaeng</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ridtitid</surname><given-names>W</given-names></name></person-group><etal>et al</etal><article-title>Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers</article-title>. <source>Biopharm Drug Dispos</source><year>2011</year>; <volume>32</volume>: <fpage>168</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">21360715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bdd.748</pub-id></mixed-citation></ref><ref id="dkz221-B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olkkola</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Aranko</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Luurila</surname><given-names>H</given-names></name></person-group><etal>et al</etal><article-title>A potentially hazardous interaction between erythromycin and midazolam</article-title>. <source>Clin Pharmacol Ther</source><year>1993</year>; <volume>53</volume>: <fpage>298</fpage>&#8211;<lpage>305</lpage>.<pub-id pub-id-type="pmid">8453848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1993.25</pub-id></mixed-citation></ref><ref id="dkz221-B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeates</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Laufen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zimmermann</surname><given-names>T.</given-names></name></person-group><article-title>Interaction between midazolam and clarithromycin: comparison with azithromycin</article-title>. <source>Int J Clin Pharmacol Ther</source><year>1996</year>; <volume>34</volume>: <fpage>400</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">8880291</pub-id></mixed-citation></ref><ref id="dkz221-B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinney</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Haehner</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Rhoades</surname><given-names>MB</given-names></name></person-group><etal>et al</etal><article-title>Interaction between midazolam and clarithromycin in the elderly</article-title>. <source>Br J Clin Pharmacol</source><year>2008</year>; <volume>65</volume>: <fpage>98</fpage>&#8211;<lpage>109</lpage>.<pub-id pub-id-type="pmid">17635500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2007.02970.x</pub-id><pub-id pub-id-type="pmcid">PMC2291277</pub-id></mixed-citation></ref><ref id="dkz221-B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yeates</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Laufen</surname><given-names>H</given-names></name></person-group><etal>et al</etal><article-title>Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam</article-title>. <source>Arzneimittelforschung</source><year>1996</year>; <volume>46</volume>: <fpage>213</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">8720318</pub-id></mixed-citation></ref><ref id="dkz221-B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattila</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Vanakoski</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Idanpaan</surname><given-names>HJJ.</given-names></name></person-group><article-title>Azithromycin does not alter the effects of oral midazolam on human performance</article-title>. <source>Eur J Clin Pharmacol</source><year>1994</year>; <volume>47</volume>: <fpage>49</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">7988623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00193477</pub-id></mixed-citation></ref><ref id="dkz221-B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagelberg</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Peltoniemi</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Saari</surname><given-names>TI</given-names></name></person-group><etal>et al</etal><article-title>Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine</article-title>. <source>Eur J Pain</source><year>2010</year>; <volume>14</volume>: <fpage>625</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19897389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpain.2009.10.003</pub-id></mixed-citation></ref><ref id="dkz221-B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Aranko</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Himberg</surname><given-names>JJ</given-names></name></person-group><etal>et al</etal><article-title>A pharmacokinetic interaction between roxithromycin and midazolam</article-title>. <source>Eur J Clin Pharmacol</source><year>1994</year>; <volume>46</volume>: <fpage>551</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">7995324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00196114</pub-id></mixed-citation></ref><ref id="dkz221-B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartkowski</surname><given-names>RR</given-names></name>, <name name-style="western"><surname>Goldberg</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Larijani</surname><given-names>GE</given-names></name></person-group><etal>et al</etal><article-title>Inhibition of alfentanil metabolism by erythromycin</article-title>. <source>Clin Pharmacol Ther</source><year>1989</year>; <volume>46</volume>: <fpage>99</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="pmid">2501060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1989.112</pub-id></mixed-citation></ref><ref id="dkz221-B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jokinen</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Olkkola</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Ahonen</surname><given-names>J</given-names></name></person-group><etal>et al</etal><article-title>Effect of ciprofloxacin on the pharmacokinetics of ropivacaine</article-title>. <source>Eur J Clin Pharmacol</source><year>2003</year>; <volume>58</volume>: <fpage>653</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">12610740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-002-0540-8</pub-id></mixed-citation></ref><ref id="dkz221-B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jokinen</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Ahonen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><etal>et al</etal><article-title>Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine</article-title>. <source>Pharmacol Toxicol</source><year>2001</year>; <volume>88</volume>: <fpage>187</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">11322176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1600-0773.2001.d01-102.x</pub-id></mixed-citation></ref><ref id="dkz221-B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jokinen</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Ahonen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><etal>et al</etal><article-title>The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine</article-title>. <source>Anesth Analg</source><year>2000</year>; <volume>91</volume>: <fpage>1207</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">11049910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000539-200011000-00030</pub-id></mixed-citation></ref><ref id="dkz221-B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liukas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hagelberg</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Kuusniemi</surname><given-names>K</given-names></name></person-group><etal>et al</etal><article-title>Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers</article-title>. <source>J Clin Psychopharmacol</source><year>2011</year>; <volume>31</volume>: <fpage>302</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21508859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JCP.0b013e3182189892</pub-id></mixed-citation></ref><ref id="dkz221-B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Bakran</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>RW</given-names></name></person-group><etal>et al</etal><article-title>Cyclosporin-erythromycin interaction in renal transplant patients</article-title>. <source>Br J Clin Pharmacol</source><year>1989</year>; <volume>27</volume>: <fpage>475</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">2655690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1989.tb05396.x</pub-id><pub-id pub-id-type="pmcid">PMC1379727</pub-id></mixed-citation></ref><ref id="dkz221-B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freeman</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Martell</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Carruthers</surname><given-names>SG</given-names></name></person-group><etal>et al</etal><article-title>Cyclosporin-erythromycin interaction in normal subjects</article-title>. <source>Br J Clin Pharmacol</source><year>1987</year>; <volume>23</volume>: <fpage>776</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">3606938</pub-id><pub-id pub-id-type="pmcid">PMC1386176</pub-id></mixed-citation></ref><ref id="dkz221-B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Federico</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Carrano</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Capone</surname><given-names>D</given-names></name></person-group><etal>et al</etal><article-title>Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients&#8212;ciclosporin, tacrolimus and levofloxacin in renal transplantation</article-title>. <source>Clin Pharmacokinet</source><year>2006</year>; <volume>45</volume>: <fpage>169</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">16485913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200645020-00003</pub-id></mixed-citation></ref><ref id="dkz221-B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrishko</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Primmett</surname><given-names>DR</given-names></name></person-group><etal>et al</etal><article-title>Investigation of a possible interaction between ciprofloxacin and cyclosporine in renal transplant patients</article-title>. <source>Transplantation</source><year>1997</year>; <volume>64</volume>: <fpage>996</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9381548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199710150-00011</pub-id></mixed-citation></ref><ref id="dkz221-B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Trull</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Shawket</surname><given-names>S.</given-names></name></person-group><article-title>Co-administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction</article-title>. <source>Br J Clin Pharmacol</source><year>1989</year>; <volume>28</volume>: <fpage>185</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">2775624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1989.tb05414.x</pub-id><pub-id pub-id-type="pmcid">PMC1379903</pub-id></mixed-citation></ref><ref id="dkz221-B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedaya</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>El-Afify</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>El-Maghraby</surname><given-names>GM.</given-names></name></person-group><article-title>The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers</article-title>. <source>Biopharm Drug Dispos</source><year>2006</year>; <volume>27</volume>: <fpage>103</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">16372380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bdd.488</pub-id></mixed-citation></ref><ref id="dkz221-B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muirhead</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Faulkner</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Harness</surname><given-names>JA</given-names></name></person-group><etal>et al</etal><article-title>The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers</article-title>. <source>Br J Clin Pharmacol</source><year>2002</year>; <volume>53 Suppl 1</volume>: <fpage>37S</fpage>&#8211;<lpage>43S</lpage>.<pub-id pub-id-type="pmid">11879258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.0306-5251.2001.00031.x</pub-id><pub-id pub-id-type="pmcid">PMC1874259</pub-id></mixed-citation></ref><ref id="dkz221-B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinde</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>JS</given-names></name></person-group><etal>et al</etal><article-title>Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects</article-title>. <source>J Clin Pharmacol</source><year>2013</year>; <volume>53</volume>: <fpage>550</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23381968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.69</pub-id></mixed-citation></ref><ref id="dkz221-B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Bae</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Shim</surname><given-names>EJ</given-names></name></person-group><etal>et al</etal><article-title>Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism</article-title>. <source>Xenobiotica</source><year>2013</year>; <volume>43</volume>: <fpage>211</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22830954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/00498254.2012.706722</pub-id></mixed-citation></ref><ref id="dkz221-B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bassi</surname><given-names>PU</given-names></name>, <name name-style="western"><surname>Onyeji</surname><given-names>CO</given-names></name>, <name name-style="western"><surname>Ukponmwan</surname><given-names>OE.</given-names></name></person-group><article-title>Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers</article-title>. <source>Br J Clin Pharmacol</source><year>2004</year>; <volume>58</volume>: <fpage>52</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">15206992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2004.02087.x</pub-id><pub-id pub-id-type="pmcid">PMC1884545</pub-id></mixed-citation></ref><ref id="dkz221-B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pohl</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Osterloh</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Gotteland</surname><given-names>JP.</given-names></name></person-group><article-title>Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate</article-title>. <source>J Clin Pharm Ther</source><year>2013</year>; <volume>38</volume>: <fpage>512</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">24102384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcpt.12098</pub-id></mixed-citation></ref><ref id="dkz221-B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yano</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tani</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name></person-group><etal>et al</etal><article-title>Evaluation of potential interaction between vinorelbine and clarithromycin</article-title>. <source>Ann Pharmacother</source><year>2009</year>; <volume>43</volume>: <fpage>453</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19261952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1345/aph.1L432</pub-id></mixed-citation></ref><ref id="dkz221-B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terkeltaub</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Furst</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Digiacinto</surname><given-names>JL</given-names></name></person-group><etal>et al</etal><article-title>Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors</article-title>. <source>Arthritis Rheum</source><year>2011</year>; <volume>63</volume>: <fpage>2226</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">21480191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.30389</pub-id></mixed-citation></ref><ref id="dkz221-B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovarik</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Beyer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bizot</surname><given-names>MN</given-names></name></person-group><etal>et al</etal><article-title>Effect of multiple-dose erythromycin on everolimus pharmacokinetics</article-title>. <source>Eur J Clin Pharmacol</source><year>2005</year>; <volume>61</volume>: <fpage>35</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15785960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-004-0866-5</pub-id></mixed-citation></ref><ref id="dkz221-B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovarik</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>McMahon</surname><given-names>L</given-names></name></person-group><etal>et al</etal><article-title>Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications</article-title>. <source>Clin Pharmacol Ther</source><year>2001</year>; <volume>70</volume>: <fpage>247</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">11557912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2001.118022</pub-id></mixed-citation></ref><ref id="dkz221-B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granfors</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism</article-title>. <source>Clin Pharmacol Ther</source><year>2004</year>; <volume>76</volume>: <fpage>598</fpage>&#8211;<lpage>606</lpage>.<pub-id pub-id-type="pmid">15592331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2004.08.018</pub-id></mixed-citation></ref><ref id="dkz221-B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Allwood</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Shawket</surname><given-names>S.</given-names></name></person-group><article-title>Effect of ciprofloxacin on the pharmacokinetics of antipyrine in healthy volunteers</article-title>. <source>J Clin Pharm Ther</source><year>1990</year>; <volume>15</volume>: <fpage>151</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">2341493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2710.1990.tb00370.x</pub-id></mixed-citation></ref><ref id="dkz221-B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludwig</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Szekely</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Csiba</surname><given-names>A</given-names></name></person-group><etal>et al</etal><article-title>The effect of ciprofloxacin on antipyrine metabolism</article-title>. <source>J Antimicrob Chemother</source><year>1988</year>; <volume>22</volume>: <fpage>61</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">3170391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/22.1.61</pub-id></mixed-citation></ref><ref id="dkz221-B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamali</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>ML.</given-names></name></person-group><article-title>Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole</article-title>. <source>Br J Clin Pharmacol</source><year>1996</year>; <volume>41</volume>: <fpage>125</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">8838438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1996.tb00169.x</pub-id></mixed-citation></ref><ref id="dkz221-B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Medina</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><etal>et al</etal><article-title>Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions</article-title>. <source>Ann Intern Med</source><year>1989</year>; <volume>110</volume>: <fpage>606</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">2784648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-110-8-606</pub-id></mixed-citation></ref><ref id="dkz221-B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piccolo</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Toossi</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Goldman</surname><given-names>M.</given-names></name></person-group><article-title>Effect of coadministration of a nutritional supplement on ciprofloxacin absorption</article-title>. <source>Am J Hosp Pharm</source><year>1994</year>; <volume>51</volume>: <fpage>2697</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">7856583</pub-id></mixed-citation></ref><ref id="dkz221-B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penttila</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Hurme</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ.</given-names></name></person-group><article-title>Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man</article-title>. <source>Eur J Clin Pharmacol</source><year>1975</year>; <volume>9</volume>: <fpage>131</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">786686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00614009</pub-id></mixed-citation></ref><ref id="dkz221-B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kays</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Overholser</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Mueller</surname><given-names>BA</given-names></name></person-group><etal>et al</etal><article-title>Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin</article-title>. <source>Am J Kidney Dis</source><year>2003</year>; <volume>42</volume>: <fpage>1253</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">14655198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2003.08.027</pub-id></mixed-citation></ref><ref id="dkz221-B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ueno</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Imano</surname><given-names>H</given-names></name></person-group><etal>et al</etal><article-title>Impairment of ciprofloxacin absorption by calcium polycarbophil</article-title>. <source>J Clin Pharmacol</source><year>2002</year>; <volume>42</volume>: <fpage>806</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">12092748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/009127002401102641</pub-id></mixed-citation></ref><ref id="dkz221-B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lesko</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Offman</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Brew</surname><given-names>CT</given-names></name></person-group><etal>et al</etal><article-title>Evaluation of the potential for drug interactions with patiromer in healthy volunteers</article-title>. <source>J Cardiovasc Pharmacol Ther</source><year>2017</year>; <volume>22</volume>: <fpage>434</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">28585859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1074248417691135</pub-id><pub-id pub-id-type="pmcid">PMC5555446</pub-id></mixed-citation></ref><ref id="dkz221-B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>How</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Arruda</surname><given-names>JA</given-names></name></person-group><etal>et al</etal><article-title>Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin</article-title>. <source>Clin J Am Soc Nephrol</source><year>2007</year>; <volume>2</volume>: <fpage>1235</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">17913970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.01580407</pub-id></mixed-citation></ref><ref id="dkz221-B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landersdorfer</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Kirkpatrick</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Kinzig</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid</article-title>. <source>Br J Clin Pharmacol</source><year>2010</year>; <volume>69</volume>: <fpage>167</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">20233180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2009.03564.x</pub-id><pub-id pub-id-type="pmcid">PMC2824478</pub-id></mixed-citation></ref><ref id="dkz221-B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaehde</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Sorgel</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Reiter</surname><given-names>A</given-names></name></person-group><etal>et al</etal><article-title>Effect of probenecid on the distribution and elimination of ciprofloxacin in humans</article-title>. <source>Clin Pharmacol Ther</source><year>1995</year>; <volume>58</volume>: <fpage>532</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">7586947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0009-9236(95)90173-6</pub-id></mixed-citation></ref><ref id="dkz221-B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolhuis</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>van Altena</surname><given-names>R</given-names></name>, <name name-style="western"><surname>van Soolingen</surname><given-names>D</given-names></name></person-group><etal>et al</etal><article-title>Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients</article-title>. <source>Eur Respir J</source><year>2013</year>; <volume>42</volume>: <fpage>1614</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">23520311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/09031936.00001913</pub-id></mixed-citation></ref><ref id="dkz221-B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>PB.</given-names></name></person-group><article-title>Therapeutic drug monitoring of psychotropic medications</article-title>. <source>Br J Clin Pharmacol</source><year>2000</year>; <volume>49</volume>: <fpage>303</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">10759685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2000.00174.x</pub-id><pub-id pub-id-type="pmcid">PMC2014933</pub-id></mixed-citation></ref><ref id="dkz221-B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickinson</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>NH</given-names></name></person-group><etal>et al</etal><article-title>Drug interactions between oral contraceptives and antibiotics</article-title>. <source>Obstet Gynecol</source><year>2001</year>; <volume>98</volume>: <fpage>853</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">11704183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0029-7844(01)01532-0</pub-id></mixed-citation></ref><ref id="dkz221-B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pemberton</surname><given-names>MN.</given-names></name></person-group><article-title>Antibiotics and oral contraceptives: new considerations for dental practice</article-title>. <source>Br Dent J</source><year>2012</year>; <volume>212</volume>: <fpage>481</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">22627223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bdj.2012.414</pub-id></mixed-citation></ref><ref id="dkz221-B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albert</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Schuller</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Network</surname><given-names>C.</given-names></name></person-group><article-title>Macrolide antibiotics and the risk of cardiac arrhythmias</article-title>. <source>Am J Respir Crit Care Med</source><year>2014</year>; <volume>189</volume>: <fpage>1173</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">24707986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201402-0385CI</pub-id><pub-id pub-id-type="pmcid">PMC4061901</pub-id></mixed-citation></ref><ref id="dkz221-B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabibian</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Gutierrez</surname><given-names>MA.</given-names></name></person-group><article-title>Doxycycline-induced pseudotumor cerebri</article-title>. <source>South Med J</source><year>2009</year>; <volume>102</volume>: <fpage>310</fpage>&#8211;<lpage>1</lpage>.<pub-id pub-id-type="pmid">19204639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SMJ.0b013e31818f98f0</pub-id></mixed-citation></ref><ref id="dkz221-B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Monadian</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Groot</surname><given-names>N</given-names></name></person-group><etal>et al</etal><article-title>QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors</article-title>. <source>Br J Clin Pharmacol</source><year>2018</year>; <volume>84</volume>: <fpage>369</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">29057492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13457</pub-id><pub-id pub-id-type="pmcid">PMC5777440</pub-id></mixed-citation></ref><ref id="dkz221-B203"><label>203</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Baxter</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Preston</surname><given-names>C.</given-names></name></person-group><source>Stockley's Drug Interactions</source><italic toggle="yes">.</italic><publisher-loc>London</publisher-loc>: 
<publisher-name>Pharmaceutical Press</publisher-name>, <year>2010</year>.</mixed-citation></ref><ref id="dkz221-B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siedlik</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Olson</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>BB</given-names></name></person-group><etal>et al</etal><article-title>Erythromycin coadministration increases plasma atorvastatin concentrations</article-title>. <source>J Clin Pharmacol</source><year>1999</year>; <volume>39</volume>: <fpage>501</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">10234598</pub-id></mixed-citation></ref><ref id="dkz221-B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ericsson</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Feldman</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pickering</surname><given-names>LK</given-names></name></person-group><etal>et al</etal><article-title>Influence of subsalicylate bismuth on absorption of doxycycline</article-title>. <source>JAMA</source><year>1982</year>; <volume>247</volume>: <fpage>2266</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">7040708</pub-id></mixed-citation></ref><ref id="dkz221-B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markert</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Schweizer</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hellwig</surname><given-names>R</given-names></name></person-group><etal>et al</etal><article-title>Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers</article-title>. <source>Br J Clin Pharmacol</source><year>2014</year>; <volume>77</volume>: <fpage>141</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23738582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.12177</pub-id><pub-id pub-id-type="pmcid">PMC3895355</pub-id></mixed-citation></ref><ref id="dkz221-B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markert</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hellwig</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name></person-group><etal>et al</etal><article-title>Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1</article-title>. <source>Eur J Clin Pharmacol</source><year>2013</year>; <volume>69</volume>: <fpage>1785</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">23748747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-013-1529-1</pub-id></mixed-citation></ref><ref id="dkz221-B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tokairin</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fukasawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yasui-Furukori</surname><given-names>N</given-names></name></person-group><etal>et al</etal><article-title>Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism</article-title>. <source>Br J Clin Pharmacol</source><year>2005</year>; <volume>60</volume>: <fpage>172</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">16042670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2005.02380.x</pub-id><pub-id pub-id-type="pmcid">PMC1884921</pub-id></mixed-citation></ref><ref id="dkz221-B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Antal</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>RB.</given-names></name></person-group><article-title>A pharmacokinetic drug interaction between erythromycin and triazolam</article-title>. <source>J Clin Psychopharmacol</source><year>1986</year>; <volume>6</volume>: <fpage>297</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">3771812</pub-id></mixed-citation></ref><ref id="dkz221-B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aranko</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Luurila</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name></person-group><etal>et al</etal><article-title>The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone</article-title>. <source>Br J Clin Pharmacol</source><year>1994</year>; <volume>38</volume>: <fpage>363</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">7833227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1994.tb04367.x</pub-id><pub-id pub-id-type="pmcid">PMC1364781</pub-id></mixed-citation></ref><ref id="dkz221-B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlase</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Popa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Neag</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers</article-title>. <source>Eur J Drug Metab Pharmacokinet</source><year>2011</year>; <volume>35</volume>: <fpage>83</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21302033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13318-010-0014-9</pub-id></mixed-citation></ref><ref id="dkz221-B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polk</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Healy</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Sahai</surname><given-names>J</given-names></name></person-group><etal>et al</etal><article-title>Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers</article-title>. <source>Antimicrob Agents Chemother</source><year>1989</year>; <volume>33</volume>: <fpage>1841</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">2610494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.33.11.1841</pub-id><pub-id pub-id-type="pmcid">PMC172774</pub-id></mixed-citation></ref><ref id="dkz221-B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hasinoff</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>McKay</surname><given-names>DW</given-names></name></person-group><etal>et al</etal><article-title>Clinical and chemical interactions between iron preparations and ciprofloxacin</article-title>. <source>Br J Clin Pharmacol</source><year>1991</year>; <volume>31</volume>: <fpage>257</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">2054264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1991.tb05526.x</pub-id><pub-id pub-id-type="pmcid">PMC1368349</pub-id></mixed-citation></ref><ref id="dkz221-B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehto</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kivisto</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ.</given-names></name></person-group><article-title>The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin</article-title>. <source>Br J Clin Pharmacol</source><year>1994</year>; <volume>37</volume>: <fpage>82</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">8148225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1994.tb04245.x</pub-id><pub-id pub-id-type="pmcid">PMC1364716</pub-id></mixed-citation></ref><ref id="dkz221-B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gothoni</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Mattila</surname><given-names>M</given-names></name></person-group><etal>et al</etal><article-title>Iron-tetracycline interaction: effect of time interval between the drugs</article-title>. <source>Acta Med Scand</source><year>1972</year>; <volume>191</volume>: <fpage>409</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">5031537</pub-id></mixed-citation></ref><ref id="dkz221-B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leyden</surname><given-names>JJ.</given-names></name></person-group><article-title>Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron</article-title>. <source>J Am Acad Dermatol</source><year>1985</year>; <volume>12</volume>: <fpage>308</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">3838321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0190-9622(85)80041-4</pub-id></mixed-citation></ref><ref id="dkz221-B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Penttila</surname><given-names>O.</given-names></name></person-group><article-title>Effect of oral ferrous sulphate on the half-life of doxycycline in man</article-title>. <source>Eur J Clin Pharmacol</source><year>1974</year>; <volume>7</volume>: <fpage>361</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">4607747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00558207</pub-id></mixed-citation></ref><ref id="dkz221-B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Turakka</surname><given-names>H.</given-names></name></person-group><article-title>Inhibitory effect of various iron salts on the absorption of tetracycline in man</article-title>. <source>Eur J Clin Pharmacol</source><year>1974</year>; <volume>7</volume>: <fpage>357</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">4213690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00558206</pub-id></mixed-citation></ref><ref id="dkz221-B219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venho</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Salonen</surname><given-names>RO</given-names></name>, <name name-style="western"><surname>Mattila</surname><given-names>MJ.</given-names></name></person-group><article-title>Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal</article-title>. <source>Eur J Clin Pharmacol</source><year>1978</year>; <volume>14</volume>: <fpage>277</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">729621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00560462</pub-id></mixed-citation></ref><ref id="dkz221-B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stass</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kubitza</surname><given-names>D.</given-names></name></person-group><article-title>Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans</article-title>. <source>Clin Pharmacokinet</source><year>2001</year>; <volume>40 Suppl 1</volume>: <fpage>57</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">11352443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200140001-00008</pub-id></mixed-citation></ref><ref id="dkz221-B221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>White</surname><given-names>A.</given-names></name></person-group><article-title>Effect of orally administered neomycin on the absorption of penicillin V</article-title>. <source>N Engl J Med</source><year>1962</year>; <volume>267</volume>: <fpage>1296</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">14020544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM196212202672506</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>